


FORM PTO-1500 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 015280-382100US	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/856927	
INTERNATIONAL APPLICATION NO. PCT/US99/28107		INTERNATIONAL FILING DATE November 24, 1999		PRIORITY DATE CLAIMED November 30, 1998	
TITLE OF INVENTION AN ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN RESISTANCE					
APPLICANT(S) FOR DO/EO/US MICHAEL DEAN, RANDO ALLIKMETS, SUSAN E. BATES, ANTONIO T. FOJO					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 . 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 36 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 37(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 36 U.S.C. 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information:					

29 MAY 2001

US/ Application No. (If known, fill in CFR 1.53) 097/856927		INTERNATIONAL APPLICATION NO PCT/US99/28107		ATTORNEY'S DOCKET NUMBER 015280-382100US																																														
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(A)(1) - (5)):				CALCULATIONS PTO USE ONLY																																														
Neither international preliminary examination fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search report prepared by the EPO of JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)(4) \$100.00				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</td> <td style="text-align: right;">\$860</td> </tr> <tr> <td colspan="3"> Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). </td> </tr> <tr> <td style="text-align: center;">CLAIMS</td> <td style="text-align: center;">NUMBER FILED</td> <td style="text-align: center;">NUMBER EXTRA</td> </tr> <tr> <td>Total claims</td> <td style="text-align: center;">20 - 20 =</td> <td></td> </tr> <tr> <td>Independent claims</td> <td style="text-align: center;">6 - 3 =</td> <td style="text-align: center;">+3</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td style="text-align: center;">+ 270.00</td> </tr> <tr> <td colspan="2" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td style="text-align: right;">\$1,100</td> </tr> <tr> <td colspan="3"> <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. </td> </tr> <tr> <td colspan="2" style="text-align: right;">SUBTOTAL =</td> <td style="text-align: right;">\$1,100</td> </tr> <tr> <td colspan="3"> Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). </td> </tr> <tr> <td colspan="2" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td></td> </tr> <tr> <td colspan="3"> Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + </td> </tr> <tr> <td colspan="2" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td style="text-align: right;">\$1,100</td> </tr> <tr> <td colspan="2" style="text-align: right;">Amount to be refunded:</td> <td style="text-align: right;">\$</td> </tr> <tr> <td colspan="2" style="text-align: right;">charged:</td> <td style="text-align: right;">\$</td> </tr> </table>		ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860	Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			CLAIMS	NUMBER FILED	NUMBER EXTRA	Total claims	20 - 20 =		Independent claims	6 - 3 =	+3	MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ 270.00	TOTAL OF ABOVE CALCULATIONS =		\$1,100	<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			SUBTOTAL =		\$1,100	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			TOTAL NATIONAL FEE =			Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			TOTAL FEES ENCLOSED =		\$1,100	Amount to be refunded:		\$	charged:		\$
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860																																																
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).																																																		
CLAIMS	NUMBER FILED	NUMBER EXTRA																																																
Total claims	20 - 20 =																																																	
Independent claims	6 - 3 =	+3																																																
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ 270.00																																																
TOTAL OF ABOVE CALCULATIONS =		\$1,100																																																
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.																																																		
SUBTOTAL =		\$1,100																																																
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).																																																		
TOTAL NATIONAL FEE =																																																		
Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +																																																		
TOTAL FEES ENCLOSED =		\$1,100																																																
Amount to be refunded:		\$																																																
charged:		\$																																																
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>20-1430</u> in the amount of <u>\$1,100</u> to cover the above fees. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>20-1430</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																																																		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																																																		
SEND ALL CORRESPONDENCE TO: Kenneth A. Weber Townsend and Townsend and Crew LLP Two Embarcadero Center, 8th fl. San Francisco, CA 94111																																																		
				 SIGNATURE																																														
				<u>Kenneth A. Weber</u> NAME																																														
				<u>31,677</u> REGISTRATION NUMBER																																														

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-382100US

Assistant Commissioner for Patents
Washington, D.C. 20231

On _____

TOWNSEND and TOWNSEND and CREW LLP

By: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DEAN *et al.*

Application No.: 09/856,927

Filed: May 29, 2001

For: A NOVEL ATP-BINDING
CASSETTE PROTEIN RESPONSIBLE
FOR CYTOTOXIN RESISTANCE

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed July 19, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

09856927.091901

In the Specification:

Please replace the paragraph beginning at page 17, line 21 with the following:

--MXR1 polymorphic variants, alleles, and interspecies homologs that are substantially identical to MXR1 can also be isolated using MXR1 nucleic acid probes, and oligonucleotides under stringent hybridization conditions, by screening libraries. Alternatively, expression libraries can be used to clone MXR1 polymorphic variants, alleles, and interspecies homologs, by detecting homologs immunologically with antisera or purified antibodies made against MXR1, which also recognize and selectively bind to the MXR1 homolog.--

Please replace the paragraph beginning at page 17, line 28 with the following:

--To make a cDNA library, one should choose a source that is rich in the *MXR1* mRNA, e.g., human colon carcinoma cells. Placenta tissue or fetal brain or liver tissue. The mRNA is then made into cDNA using reverse transcriptase, ligated into a recombinant vector, and transfected into a recombinant host for propagation, screening, and cloning. Methods for making and screening cDNA libraries are well known (see, e.g., Gubler & Hoffman, *Gene* 25:263-269 (1983); Sambrook et al. *supra*; Ausubel et al., *supra*).--

Please replace the paragraph beginning at page 18, line 3 with the following:

--An alternative method of isolating *MXR1* nucleic acids and their homologs combines the use of synthetic oligonucleotide primers and amplification of an RNA or DNA template (see US Patents 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (Innis et al., eds 1990)). Methods such as polymerase chain reaction (PCR) and ligase chain reaction (LCR) can be used to amplify

09856927.091901

nucleic acid sequences of ABC proteins directly from mRNA, from cDNA, from genomic libraries or cDNA libraries. Degenerate oligonucleotides can be designed to amplify ABC homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers. PCR or other in vitro amplification methods may be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of ABC protein encoding mRNA in physiological samples, for nucleic acid sequencing, or for other purposes. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.--

Please replace the paragraph beginning at page 19, line 7 with the following:

--To obtain high level expression of a cloned gene or nucleic acid, such as those cDNAs encoding the ABC protein MXR1, one typically subclones *MXR1* into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.* and Ausubel *et al.* Bacterial expression systems for expressing MXR1 are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.--

Please replace the paragraph beginning at page 21, line 3 with the following:

--Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of MXR1 protein, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.*

09856927.091901

264:17619-17622 (1989); *Guide to Protein Purification*, in *Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g.*, Morrison, *J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983).--

Please replace the paragraph beginning at page 21, line 11 with the following:

--Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g.*, Sambrook *et al.*, *supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing MXR1 protein.--

Please replace the paragraph beginning at page 27, line 16 with the following:

--Thus, in accordance with preferred embodiments of this invention, preferred antisense molecules include oligonucleotides and oligonucleotide analogs that are hybridizable with *MXR1* mRNA. This relationship is commonly denominated as "antisense." The oligonucleotides and oligonucleotide analogs are able to inhibit the function of the RNA, either its translation into protein, its translocation into the cytoplasm, or any other activity necessary to its overall biological function. The failure of the messenger RNA to perform all or part of its function results in a reduction or complete inhibition of expression of MXR1 polypeptides.--

09856927.091901

Please replace the paragraph beginning at page 37, line 21 with the following:

--cDNA libraries constructed with the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (GIBCO-BRL, Rockville MD) using mRNA from mitoxantrone resistant S1-M1-80 human colon carcinoma cells can be used to isolate the MXR1 nucleic acids of the invention.--

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 8, at the end of the application.

In the Claims:

Please amend claims 1-3, 7-13, 17 and 18 as follows:

1. (Amended) An isolated ATP-binding cassette protein having the following properties:
 - i. conferring mitoxantrone resistance to a S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
 - ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4; and
 - iii. having a molecular weight between about 70 kDa and about 75 kDa.
2. (Amended) The ATP-binding cassette protein of claim 1 wherein the protein has 95% identity to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

09856927-091901

3. (Amended) A eukaryote cell genetically altered to overexpress an ATP-binding cassette protein having the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4.

7. (Amended) A DNA encoding a ATP-binding cassette protein wherein the protein is characterized by having the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins consisting of those depicted in SEQ ID NO:2 or SEQ ID NO:4.

8. (Amended) The DNA of claim 7, wherein the encoded protein has 95% identity to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

9. (Amended) The DNA of claim 7, wherein the DNA encoding the protein has a sequence identical to that depicted in SEQ ID NO:1 or SEQ ID NO:3.

09856927.001901

10. (Amended) A process for over expressing ATP-binding cassette protein in a cell comprising a first step of either:

i. transforming the cell with an expression cassette which directs the expression of ATP-binding cassette protein; or,

ii. selecting a cell having an endogenous copy of the ATP-binding cassette protein, and transforming the cell with DNA which can serve as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein; and a second step of,

culturing the transformed cell under conditions where the levels of ATP-binding cassette protein are increased above the basal levels of the non-transformed cells with the proviso that the ATP-binding cassette protein has the following properties:

a. confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,

b. specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4.

11. (Amended) The process of claim 10, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

12. (Amended) The process of claim 10, wherein the protein has the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

09856927.001501

13. (Amended) A method of screening for inhibitors of cytotoxin resistance in cells comprising the steps of :

(a) culturing a cell genetically altered by the introduction of heterologous DNA which permits the overexpression an ATP-binding cassette protein where the protein has the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4;

(b) contacting the cell with a cytotoxin in an amount that permits cell survival due to the resistance conferred by the ATP-binding cassette protein;

(c) contacting the cell with a compound that inhibits the biological activity of the ATP-binding cassette protein;

(d) detecting the inhibition by measuring growth inhibition of the cells.

17. (Amended) A method of claim 13, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

18. (Amended) A binding protein which specifically binds to an ATP-binding cassette protein which has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

09856927-091901

REMARKS

The amendments to paragraphs beginning on 17, 18, 19, 21, 27, and 37 were made to clarify the nomenclature used for the nucleic acid and amino acid sequences of the invention. All reference to MXR2 genes and proteins have been removed, since no sequences identified as such are present in the Specification or informal Sequence Listing addendum. In addition all reference to an MXR sequence has been changed to consistently reflect the MXR1 usage in the remainder of the Specification.

Claims 1-20 are pending in this application. Claims 1-3, 7-13, 17 and 18 have been amended. The amendments to claims 1-3, 7-13, 17 and 18 correct the format of the SEQ ID NO: assigned identifiers for sequences designated in these claims in accordance with 37 C.F.R. §§1.821(2)(d) and WIPO Standard ST.25.

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-6, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.


Attached hereto is a marked-up version of the changes made to the Specification and Claims by the current Amendment. The attached pages are captioned **"VERSION WITH MARKINGS TO SHOW CHANGES MADE."** As a convenience to the Examiner, a complete set of the Claims, as amended herein, is also attached to this Amendment as an Appendix entitled **"PENDING CLAIMS WITH ENTRY OF THE AMENDMENT."**

DEAN *et al.*
Application No.: 09/856,927
Page 10

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Kenneth A. Weber
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
KAW:dmw

09/856,927-091901

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 21 of page 17 has been amended as follows:

MXR1 ~~MXR~~ polymorphic variants, alleles, and interspecies homologs that are substantially identical to MXR1 ~~and MXR2~~ can also be isolated using MXR1 ~~and MXR-2~~ nucleic acid probes, and oligonucleotides under stringent hybridization conditions, by screening libraries. Alternatively, expression libraries can be used to clone MXR1 ~~and MXR2~~ polymorphic variants, alleles, and interspecies homologs, by detecting homologs immunologically with antisera or purified antibodies made against MXR1 ~~or MXR2~~, which also recognize and selectively bind to the MXR1 ~~or MXR2~~ homolog.

Paragraph beginning at line 28 of page 17 has been amended as follows:

To make a cDNA library, one should choose a source that is rich in the MXR1 ~~MXR~~ mRNA, e.g., human colon carcinoma cells. Placenta tissue or fetal brain or liver tissue. The mRNA is then made into cDNA using reverse transcriptase, ligated into a recombinant vector, and transfected into a recombinant host for propagation, screening, and cloning. Methods for making and screening cDNA libraries are well known (see, e.g., Gubler & Hoffman, *Gene* 25:263-269 (1983); Sambrook et al. *supra*; Ausubel et al., *supra*).

Paragraph beginning at line 3 of page 18 has been amended as follows:

An alternative method of isolating MXR1 ~~MXR~~ nucleic acids and their homologs combines the use of synthetic oligonucleotide primers and amplification of an

09856927.091001

RNA or DNA template (see US Patents 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (Innis et al., ed-s 1990)). Methods such as polymerase chain reaction (PCR) and ligase chain reaction (LCR) can be used to amplify nucleic acid sequences of ABC proteins directly from mRNA, from cDNA, from genomic libraries or cDNA libraries. Degenerate oligonucleotides can be designed to amplify ABC homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers. PCR or other in vitro amplification methods may be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of ABC protein encoding mRNA in physiological samples, for nucleic acid sequencing, or for other purposes. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.

Paragraph beginning at line 7 of page 19 has been amended as follows:

To obtain high level expression of a cloned gene or nucleic acid, such as those cDNAs encoding the ABC protein MXR1, one typically subclones MXR1 ~~MXR~~ into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.* and Ausubel *et al.* Bacterial expression systems for expressing MXR1 are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.

09856927.091901

Paragraph beginning at line 3 of page 21 has been amended as follows:

Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of MXR1 ~~MXR~~ protein, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.* 264:17619-17622 (1989); *Guide to Protein Purification*, in *Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g., Morrison, J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983).

Paragraph beginning at line 11 of page 21 has been amended as follows:

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g., Sambrook et al., supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing MXR1 ~~MXR~~ protein.

Paragraph beginning at line 16 of page 27 has been amended as follows:

Thus, in accordance with preferred embodiments of this invention, preferred antisense molecules include oligonucleotides and oligonucleotide analogs that are hybridizable with *MXR1* mRNA. This relationship is commonly denominated as "antisense." The oligonucleotides and oligonucleotide analogs are able to inhibit the function of the RNA, either its translation into protein, its translocation into the

09856927-091901

cytoplasm, or any other activity necessary to its overall biological function. The failure of the messenger RNA to perform all or part of its function results in a reduction or complete inhibition of expression of MXR1 ~~MXR~~ polypeptides.

Paragraph beginning at line 21 of page 37 has been amended as follows:

cDNA libraries constructed with the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (GIBCO-BRL, Rockville MD) using mRNA from mitoxantrone resistant S1-M1-80 human colon carcinoma cells can be used to isolate the MXR1 and ~~MXR2~~ nucleic acids of the invention.

In the Claims:

Claims 1-3, 7-13, 17 and 18 have been amended as follows:

1. (Amended) An isolated ATP-binding cassette protein having the following properties:

- i. conferring mitoxantrone resistance to a S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4~~; and
- iii. having a molecular weight between about 70 kDa and about 75 kDa.

2. (Amended) The ATP-binding cassette protein of claim 1 wherein the protein has 95% identity to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4~~.

09856927.091901

3. (Amended) A eukaryote cell genetically altered to overexpress an ATP-binding cassette protein having the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4.~~

7. (Amended) A DNA encoding a ATP-binding cassette protein wherein the protein is characterized by having the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins consisting of those depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4.~~

8. (Amended) The DNA of claim 7, wherein the encoded protein has 95% identity to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4.~~

9. (Amended) The DNA of claim 7, wherein the DNA encoding the protein has a sequence identical to that depicted in SEQ ID NO:1 or SEQ ID NO:3 ~~Seq. ID. No. 1 or No. 3.~~

09856927.091601

10. (Amended) A process for over expressing ATP-binding cassette protein in a cell comprising a first step of either:

- i. transforming the cell with an expression cassette which directs the expression of ATP-binding cassette protein; or,
- ii. selecting a cell having an endogenous copy of the ATP-binding cassette protein, and transforming the cell with DNA which can serve as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein; and a second step of,

culturing the transformed cell under conditions where the levels of ATP-binding cassette protein are increased above the basal levels of the non-transformed cells with the proviso that the ATP-binding cassette protein has the following properties:

- a. confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- b. specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4 Seq. ID. No. 2 or ID. No. 4.

11. (Amended) The process of claim 10, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4 Seq. ID. No. 2 or ID. No. 4.

12. (Amended) The process of claim 10, wherein the protein has the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4 Seq. ID. No. 2 or ID. No. 4.

09856927.091901

13. (Amended) A method of screening for inhibitors of cytotoxin resistance in cells comprising the steps of :

- (a) culturing a cell genetically altered by the introduction of heterologous DNA which permits the overexpression an ATP-binding cassette protein where the protein has the following properties:
 - i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
 - ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4~~;
- (b) contacting the cell with a cytotoxin in an amount that permits cell survival due to the resistance conferred by the ATP-binding cassette protein;
- (c) contacting the cell with a compound that inhibits the biological activity of the ATP-binding cassette protein;
- (d) detecting the inhibition by measuring growth inhibition of the cells.

17. (Amended) A method of claim 13, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4~~.

18. (Amended) A binding protein which specifically binds to an ATP-binding cassette protein which has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4 ~~Seq. ID. No. 2 or ID. No. 4~~.

09856927.091001

PENDING CLAIMS WITH ENTRY OF THE AMENDMENT

1. (Amended) An isolated ATP-binding cassette protein having the following properties:
 - i. conferring mitoxantrone resistance to a S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
 - ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4; and
 - iii. having a molecular weight between about 70 kDa and about 75 kDa.
2. (Amended) The ATP-binding cassette protein of claim 1 wherein the protein has 95% identity to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.
3. (Amended) A eukaryote cell genetically altered to overexpress an ATP-binding cassette protein having the following properties:
 - i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
 - ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4.
4. (As filed) A cell of claim 3, wherein the cell is genetically altered by transformation of the cell with an exogenous DNA comprising an expression cassette encoding the ATP-binding cassette protein.

09856927-091901

5. (As filed) A cell of claim 4, wherein the expression cassette comprises a heterologous promoter operatively linked to the DNA encoding the ATP-binding cassette protein.

6. (As filed) A cell of claim 3, wherein the cell has an endogenous copy of the ATP-binding cassette protein and the genetic alteration comprises insertion of DNA which can serve as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein.

7. (Amended) A DNA encoding a ATP-binding cassette protein wherein the protein is characterized by having the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins consisting of those depicted in SEQ ID NO:2 or SEQ ID NO:4.

8. (Amended) The DNA of claim 7, wherein the encoded protein has 95% identity to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

9. (Amended) The DNA of claim 7, wherein the DNA encoding the protein has a sequence identical to that depicted in SEQ ID NO:1 or SEQ ID NO:3.

09856927.091001

10. (Amended) A process for over expressing ATP-binding cassette protein in a cell comprising a first step of either:

i. transforming the cell with an expression cassette which directs the expression of ATP-binding cassette protein; or,

ii. selecting a cell having an endogenous copy of the ATP-binding cassette protein, and transforming the cell with DNA which can serve as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein; and a second step of,

culturing the transformed cell under conditions where the levels of ATP-binding cassette protein are increased above the basal levels of the non-transformed cells with the proviso that the ATP-binding cassette protein has the following properties:

a. confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,

b. specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4.

11. (Amended) The process of claim 10, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

12. (Amended) The process of claim 10, wherein the protein has the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

09856927.091001

13. (Amended) A method of screening for inhibitors of cytotoxin resistance in cells comprising the steps of:

(a) culturing a cell genetically altered by the introduction of heterologous DNA which permits the overexpression an ATP-binding cassette protein where the protein has the following properties:

- i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
- ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO:2 or SEQ ID NO:4;

(b) contacting the cell with a cytotoxin in an amount that permits cell survival due to the resistance conferred by the ATP-binding cassette protein;

(c) contacting the cell with a compound that inhibits the biological activity of the ATP-binding cassette protein;

(d) detecting the inhibition by measuring growth inhibition of the cells.

14. (As filed) A method of claim 13, where the cytotoxin is mitoxantrone.

15. (As filed) A method of claim 13, where the cytotoxin is daunomycin.

16. (As filed) A method of claim 13, where the cell is a carcinoma cell.

17. (Amended) A method of claim 13, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

09856927-091901

18. (Amended) A binding protein which specifically binds to an ATP-binding cassette protein which has 95% homology to the amino acids depicted in SEQ ID NO:2 or SEQ ID NO:4.

19. (As filed) A binding protein of claim 18, wherein the binding protein is an antibody.

20. (As filed) A binding protein of claim 18, wherein the binding protein is a monoclonal antibody.

09/856927

AN ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN RESISTANCE

5

FIELD OF THE INVENTION

This invention provides for a novel ATP-binding cassette protein which is responsible for cytotoxin resistance. The invention also provides for methods of expressing the protein and assays for identification of inhibitors of the protein.

10

RELATED APPLICATIONS

There are no related applications.

BACKGROUND OF THE INVENTION

15

20

25

30

The multidrug resistance/ATP-binding cassette (MDR/ABC) superfamily in humans includes genes whose products represent membrane proteins involved in energy-dependent transport of a wide variety of substrates across a membrane (see, e.g., Dean, M. and Aliakimets, R. (1995) Curr. Opin. Genet. Dev. 5, 79-785). The overexpression of ABC transporters has been linked with drug resistance since the 1976 discovery of P-glycoprotein and the subsequent cloning of the encoding gene, MDR-1. Resistance ensues from reduced intracellular drug concentrations, a result of active drug efflux. The subsequent identification of the multidrug resistance associated protein (MRP), encoded by the MRP gene, heralded a new era that recognized the complexity of the problem and catalyzed the search for additional transporters. MDR-1 and MRP are members of the expanding superfamily of ATP-binding cassette proteins (ABC proteins). This superfamily is comprised of a large and diverse group of proteins that transport solutes across biological membranes. Transmembrane domains are thought to form a pathway through which substrates cross cell membranes, while two ATP-binding domains hydrolyze ATP to accomplish substrate transport. Mutations in ABC transporters have been identified as etiologic in diseases including hyperinsulinemic hypoglycemia of infancy, adrenoleukodystrophy, and cystic fibrosis. The transporters

MDR-1 and MRP, and possibly the multispecific organic anion transporter, cMOAT, are thought to be involved in both normal excretion of xenobiotics and in drug resistance. The ABC superfamily also includes a number of transporters without known function and the potential exists to identify additional transporters which mediate drug resistance.

Recent studies have described a number of cell lines with resistance to mitoxantrone that exhibit multidrug resistance without overexpression of MRP. In addition to mitoxantrone, these cell lines are particularly resistant to anthracyclines, and have an energy-dependent reduction in the accumulation of daunomycin and mitoxantrone. Cell lines possessing this phenotype include sublines derived by selection of leukemic cells, as well as breast, colon, and gastric carcinomas.

SUMMARY OF THE INVENTION

The present invention thus provides for the first time, nucleic acids encoding a new transporter protein that mediates drug resistance. These proteins are generically called ATP binding cassette proteins (ABC proteins). The ABC protein of the invention is referred to as MXR1. It is also known as ABCP, and is also known as ABCG2.

In one aspect, the present invention provides an isolated ATP-binding cassette protein that confers mitoxantrone resistance to S1-M1-80 human colon carcinoma cells when expressed in the cells; and specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO. 2 or SEQ ID. NO. 4; and has a molecular weight between about 70 kDa and about 75 kDa.

In one embodiment, the MXR1 protein has the sequence depicted in SEQ ID NO. 2 or SEQ ID NO. 4. In another embodiment, the protein has 95% identity to the amino acids depicted in SEQ ID NO. 2 or SEQ ID. NO. 4.

In another aspect, the present invention provides a eukaryotic cell genetically altered to overexpress an ATP-binding cassette protein that confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO. 2 or SEQ ID. NO. 4.

In one embodiment, the cells of the invention are genetically altered by transformation of the cell with an exogenous DNA comprising an expression cassette encoding the ATP-binding cassette protein. In another embodiment, the expression

cassette also employs a heterologous promoter operatively linked to the DNA encoding the ATP-binding cassette protein. In another embodiment, the cell may have an endogenous copy of the ATP-binding cassette protein with a genetic alteration comprising insertion of DNA that serves as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein.

In another aspect, the present invention provides for DNA encoding an ATP-binding cassette protein wherein the protein confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells and specifically binds to polyclonal antibodies which specifically bind to the proteins depicted in SEQ ID NO. 2 or SEQ ID NO. 4.

In one embodiment, the DNA encodes for the protein of SEQ ID NO. 2 or SEQ ID NO. 4 and in other embodiments the DNA encodes a protein that has 95% identity to the amino acids depicted in SEQ ID NO. 2 or SEQ ID NO. 4. In another embodiment, the DNA has the sequence depicted in SEQ ID NO. 1 or SEQ ID NO. 3.

In another aspect, the present invention provides a process for over expressing ATP-binding cassette protein in a cell comprising a first step of either (1) transforming the cell with an expression cassette which directs the expression of ATP-binding cassette protein; or, (2) selecting a cell having an endogenous copy of the ATP-binding cassette protein, and transforming the cell with DNA which can serve as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein; and a second step of culturing the transformed cell under conditions where the levels of ATP-binding cassette protein are increased above the basal levels of the non-transformed cells. The ATP binding protein of this embodiment is one that confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and, specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO. 2 or SEQ ID No. 4.

In one embodiment, the ATP binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO. 2 or SEQ ID No. 4. In yet another embodiment, the protein has the amino acids depicted in SEQ ID NO. 2 or SEQ ID No. 4.

In another aspect, the present invention provides a method of screening for inhibitors of cytotoxin resistance in cells. The method comprises (1) culturing a cell genetically altered by the introduction of heterologous DNA which permits the overexpression an ATP-binding cassette protein that confers mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and specifically binds to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in SEQ ID NO. 2 or SEQ ID NO. 4; and, (2) contacting the cell with a cytotoxin in an amount that permits cell survival due to the resistance conferred by the ATP-binding cassette protein; and, (3) contacting the cell with a compound that inhibits the biological activity of the ATP-binding cassette protein; and, (4) detecting the inhibition by measuring growth inhibition of the cells.

In one embodiment, the cytotoxin is mitoxantrone. In another embodiment, the cytotoxin is daunomycin. In another embodiment, the cell is a carcinoma cell. In another embodiment, the ATP-binding cassette protein has 95% homology to the amino acids depicted in SEQ ID NO. 2 or SEQ ID NO. 4. In another embodiment, the ATP binding cassette protein has the amino acid sequence depicted in SEQ ID NO. 2 or SEQ ID NO. 4.

In another aspect, the invention provides a binding protein that specifically binds to an ATP-binding cassette protein which has 95% homology to the amino acids depicted in SEQ ID NO. 2 or SEQ ID NO. 4. In one embodiment, the binding protein is an antibody, and in another embodiment, the binding protein is a monoclonal antibody.

Non-Competitive Assay Formats.

Immunoassays for detecting the ATP binding cassette protein may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of captured analyte (in this case the protein) is directly measured. In one preferred "sandwich" assay, for example, the capture agent (anti-ABC antibodies) can be bound directly to a solid substrate where they are immobilized. These immobilized antibodies then capture the ATP binding cassette protein present in the test sample. The ATP binding cassette protein thus immobilized is then bound by a labeling agent, such as a second ATP binding cassette antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The

second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

DETAILED DESCRIPTION

Introduction

The present invention provides for the first time, nucleic acids encoding the ATP binding cassette (ABC) protein, MXR1. These nucleic acids and the subunits they encode are part of a superfamily of membrane proteins and a part of a multidrug resistance subfamily, involved in energy dependent transport of substrates across membranes. The gene which is the subject of the present invention encodes a 658 amino acid protein that is highly expressed in placenta, in fetal brain and liver, and in at least two mitoxantrone resistant cancer cell lines. The strong expression of the gene in the placenta indicates that the MXR1 protein is important in the transfer of specific molecules in or out of the placenta. The overexpression in the cancer cell lines indicates that the protein is involved with multidrug resistance in cancer cells.

The invention also provides an assay for screening for inhibitors of cytotoxin resistance in cells. The assay involves culturing a cell that has been genetically altered by the introduction of heterologous DNA which permits the overexpression of an ATP-binding cassette protein that confers mitoxantrone resistance and contacting the cell with a cytotoxin and contacting the cell with a compound that inhibits the biological activity of the ATP-binding cassette protein and detecting the inhibition by measuring growth inhibition of the cells.

Definitions

"ATP-binding cassette protein" refers to a protein having an ATP-binding cassette (ABC) (see, e.g., Allikmets et al., Human Molecular Genetics 5 ;1649-1655 (1996)) which is involved in transporting substrates across cell membranes. They are energy dependent (ATP) and have defined transmembrane domains.

As used herein, an "antibody" refers to a protein functionally defined as a binding protein and structurally defined as comprising an amino acid sequence that is recognized by one of skill as being derived from the framework region of an immunoglobulin encoding gene of an animal producing antibodies. An antibody can consist of one or more polypeptides substantially encoded by immunoglobulin genes or

fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

Antibodies exist as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab')₂, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab')₂ may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the F(ab')₂ dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (see, Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized de novo using recombinant DNA methodologies. Preferred antibodies include single chain antibodies (antibodies that exist as a single polypeptide chain), more preferably single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light chain are joined together (directly or through a peptide linker) to form a continuous polypeptide. The single chain Fv antibody is a covalently linked VH-VL heterodimer which may be expressed from a nucleic acid including VH- and VL- encoding sequences either joined directly or joined by a peptide-encoding linker. Huston, et al. (1988) Proc. Nat. Acad. Sci. USA, 85: 5879-5883. While the VH and VL are connected to each as a single polypeptide chain, the VH and VL domains associate non-covalently. The first functional antibody molecules to be

expressed on the surface of filamentous phage were single-chain Fv's (scFv), however, alternative expression strategies have also been successful. For example Fab molecules can be displayed on phage if one of the chains (heavy or light) is fused to g3 capsid protein and the complementary chain exported to the periplasm as a soluble molecule.

5 The two chains can be encoded on the same or on different replicons; the important point is that the two antibody chains in each Fab molecule assemble post-translationally and the dimer is incorporated into the phage particle via linkage of one of the chains to g3p (see, e.g., U.S. Patent No: 5733743). The scFv antibodies and a number of other structures converting the naturally aggregated, but chemically separated light and heavy polypeptide
10 chains from an antibody V region into a molecule that folds into a three dimensional structure substantially similar to the structure of an antigen-binding site are known to those of skill in the art (see e.g., U.S. Patent Nos. 5,091,513, 5,132,405, and 4,956,778). Particularly preferred antibodies include all those that have been displayed on phage (e.g., scFv, Fv, Fab and disulfide linked Fv (Reiter et al. (1995) Protein Eng. 8: 1323-1331).
15 Antibodies can also include diantibodies and miniantibodies.

An "anti-MXR1" or an "anti-ABC" antibody is an antibody or antibody fragment that specifically binds an MXR1 protein or an ATP-binding cassette protein respectively.

"Binding protein" is a general term for a protein that specifically binds to a
20 target ligand or cognate molecule. It includes either member of a binding pair. It would also include receptor-like molecules, hormones, antibodies, antigens, and importantly proteins identified as selective or specific binders from a randomized library of proteins displayed on phage.

"Endogenous" refers to a naturally occurring element of a cell or organism
25 that is naturally produced by the cell or organism as part of its normal life cycle.

"Exogenous" refers to non-naturally occurring elements of a cell which are introduced by the hand of man. Transformation of cell with nucleic acid introduces exogenous DNA elements. An exogenous DNA element usually denotes a nucleic acid that has been isolated, cloned, and ligated to a nucleic acid with which it is not combined
30 in nature, and or introduced into and /or expressed in a cell or cellular environment other than the cell or cellular environment in which said nucleic acid or protein may be found in nature. The term encompasses both nucleic acids originally obtained from a different

organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed.

A prokaryotic cell has been "transformed" by an exogenous nucleic acid when such exogenous nucleic acid has been introduced inside the cell membrane.

- 5 Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. The exogenous DNA may be maintained on an episomal element, such as a plasmid.

- 10 An "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with nucleic acid elements that are capable of effecting expression of a structural gene in hosts compatible with such sequences. Expression cassettes include at least promoters and optionally, transcription termination signals. Typically, the recombinant expression cassette includes a nucleic acid to be transcribed (e.g., a nucleic acid encoding a desired polypeptide), and a promoter. Additional factors necessary or helpful in effecting expression may also be used as described herein. For
15 example, an expression cassette can also include nucleotide sequences that encode a signal sequence that directs secretion of an expressed protein from the host cell. Transcription termination signals, enhancers, and other nucleic acid sequences that influence gene expression, can also be included in an expression cassette.

- 20 The term "over expression" refers to the situation when one or more components of cell may be present at a higher than normal cellular level (i.e., higher than the concentration known to usually be present in the cell type exhibiting the protein complex of interest). For example, the gene encoding a protein may begin to be overexpressed, or may be amplified (i.e., its gene copy number may be increased) in certain cells, leading to an increased number of component molecules within these cells.
25 Typically overexpression will result in from about 10% to about 15% over the basal expression level.

- 30 The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the

protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

The term "recombinant" when used with reference to a cell, or nucleic acid, or vector, indicates that the cell, or nucleic acid, or vector, has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence, which has a designated percent sequence or subsequence complementarity when the test sequence has a designated or substantial identity to a reference sequence. For example, a designated amino acid percent identity of 86% refers to sequences or subsequences that have at least about 86% amino acid identity when aligned for maximum correspondence over a comparison window as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Preferably, the percent identity exists over a region of

the sequence that is at least about 25 amino acids in length, more preferably over a region that is 50 amino acids in length.

When percentage of sequence identity is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated according to, e.g., the algorithm of Meyers & Miller, *Computer Applic. Biol. Sci.* 4:11-17 (1988) e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA)..

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated or default program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 25 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment

algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Ausubel et al., supra*).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux *et al., Nuc. Acids Res.* 12:387-395 (1984)).

Another example of algorithm that is suitable for determining percent sequence identity (i.e., substantial similarity or identity) is the BLAST algorithm, which is described in Altschul *et al., J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when

aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al, supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues, always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as default parameters a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.,* Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to an ATP binding cassette nucleic acid sequence, such as MXR1, if the smallest sum probability in a comparison of the test nucleic acid to the MXR1 nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

The term "substantial identity" or "substantial similarity" in the context of a polypeptide indicates that a polypeptides comprises a sequence with at least 70% sequence identity to a reference sequence, or preferably 80%, or more preferably 85% sequence identity to the reference sequence, or most preferably 90% identity over a comparison window of about 10-20 amino acid residues.

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions.

"Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

The phrase "hybridizing specifically to", refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (*e.g.*, total cellular DNA or RNA. The term "stringent conditions" refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at T_m , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

The phrases "specifically binds to a protein" or "specifically immunoreactive with", when referring to an antibody refers to a binding reaction which is

determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind preferentially to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. For determination of specific binding of an anti-ABC antibody, an immunoblot assay is preferred.

A "conservative substitution," when describing a protein refers to a change in the amino acid composition of the protein that does not substantially alter the protein's activity. Thus, "conservatively modified variations" of a particular amino acid sequence refers to amino acid substitutions of those amino acids that are not critical for protein activity or substitution of amino acids with other amino acids having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids do not substantially alter activity. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton (1984) *Proteins* W.H. Freeman and Company. One of skill in the art will appreciate that the above-identified substitutions are not the only possible conservative substitutions. For example, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In

addition, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence are also "conservatively modified variations".

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in the native state.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed or operably linked to a promoter.

The phrase "a nucleic acid sequence encoding" refers to a nucleic acid which contains sequence information for a structural RNA such as rRNA, a tRNA, or the primary amino acid sequence of a specific protein or peptide, or a binding site for a trans-acting regulatory agent. This phrase specifically encompasses degenerate codons (i.e., different codons which encode a single amino acid) of the native sequence or sequences which may be introduced to conform with codon preference in a specific host cell.

"Antisense sequence or antisense nucleic acids" are used interchangeably and refer to sequences of nucleic acids that are complementary to the coding mRNA nucleic acid sequence. The phrase specifically encompasses nucleic acid sequences that bind to mRNA or portions thereof to block transcription of mRNA by ribosomes.

"Conferring mitoxantrone resistance" refers to the situation in which the expression of a protein in a cell makes the cell resistant to a particular drug or antibiotic. For example, cells where an ABC gene is overexpressed or amplified in certain breast and colon cancer cell lines will be resistant to the chemotherapeutic drug mitoxantrone, and to a lesser extent daunorubicin, i.e., the drugs will have no effect on the cell.

"Genetically altered" refers to a protein, cell, nucleic acid or other biological molecule that has been recombinantly or otherwise manipulated such that it is no longer in its native state.

The phrase "basal expression levels" refers to the normal, base or fundamental level of protein expression in a cell in its usual environment.

"Enhancing element" refers to a component in a cell that enhances or increases the basal or normal protein expression level. Such an element will cause a cell to express more of a protein than it would under natural or normal conditions.

"Growth inhibition" refers to cell death or a slowing down or suppression of cell growth, biological function, or division. The growth inhibition can be caused by chemical or physical means.

Genes Encoding ATP-Binding Cassette Protein

10 A. General Recombinant DNA Methods

This invention relies on routine techniques in the field of recombinant genetics to produce the *MXR1* nucleic acids of the present invention. Basic texts disclosing the general methods of use in this invention include Sambrook et al., *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and*
15 *Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel et al., eds., 1994).

For nucleic acids, sizes are given in either kilobases (kb) or base pairs (bp). These are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. For proteins, sizes are given
20 in kilodaltons (kDa) or amino acid residue numbers. Protein sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.

Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester method first described by
25 Beaucage & Caruthers, *Tetrahedron Letts.* 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter et al., *Nucleic Acids Res.* 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson & Reanier, *J. Chrom.* 255:137-149 (1983).

The sequence of the cloned genes and synthetic oligonucleotides can be
30 verified after cloning using, e.g., the chain termination method for sequencing double-stranded templates of Wallace et al., *Gene* 16:21-26 (1981).

B. Cloning Methods for the Isolation of Nucleotide Sequences Encoding MXR1

In general, the nucleic acid sequences encoding the ATP binding cassette proteins and related nucleic acid homologs are cloned from cDNA and genomic DNA libraries by hybridization with a probe, or isolated using amplification techniques with oligonucleotide primers. For example, ABC proteins are typically isolated from mammalian DNA libraries by hybridizing with a nucleic acid probe, the sequence of which can be derived from SEQ ID NO: 1 or 3.. A suitable tissue from which ABC proteins and cDNA can be isolated is fetal brain or liver, and preferably placenta.

Amplification techniques using primers can also be used to amplify and isolate ABC nucleic acids from DNA or RNA. The degenerate primers encoding the following amino acid sequences can also be use to amplify a sequence of MXR1. SEQ ID NOS: 5 & 6 (Dieffnach & Dveksler, *PCR Primer: A Laboratory Manual* (1995)). These primers can be used, e.g., to amplify either the full length sequence or a probe of one to a hundred nucleotides, which is then used to screen a mammalian library for full length MXR1.

Nucleic acids encoding ABC proteins can also be isolated from expression libraries using antibodies as probes. Such polyclonal or monoclonal antibodies can be raised using the sequence of SEQ ID NO: 2 or 4

MXR polymorphic variants, alleles, and interspecies homologs that are substantially identical to MXR1 and MXR2 can also be isolated using MXR1 and MXR 2 nucleic acid probes, and oligonucleotides under stringent hybridization conditions, by screening libraries. Alternatively, expression libraries can be used to clone MXR1 and MXR2 polymorphic variants, alleles, and interspecies homologs, by detecting homologs immunologically with antisera or purified antibodies made against MXR1 or MXR2, which also recognize and selectively bind to the MXR1 or MXR2 homolog.

To make a cDNA library, one should choose a source that is rich in the MXR mRNA, e.g., human colon carcinoma cells. Placenta tissue or fetal brain or liver tissue. The mRNA is then made into cDNA using reverse transcriptase, ligated into a recombinant vector, and transfected into a recombinant host for propagation, screening, and cloning. Methods for making and screening cDNA libraries are well known (see,

e.g., Gubler & Hoffman, *Gene* 25:263-269 (1983); Sambrook et al. *supra*; Ausubel et al., *supra*).

For a genetic library, the DNA is extracted from the tissue and either mechanically sheared or enzymatically digested to yield fragments of about 12-20 kb.

5 The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are described in Benton & Davis, *Science* 196:180-182 (1977). Colony hybridization is carried out as generally described in Grunstein et al., *PNAS USA*, 72:3961-3965 (1975).

An alternative method of isolating *MXR* nucleic acids and their homologs
10 combines the use of synthetic oligonucleotide primers and amplification of an RNA or DNA template (see US Patents 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (Innis et al., ed.s 1990)). Methods such as polymerase chain reaction (PCR) and ligase chain reaction (LCR) can be used to amplify nucleic acid sequences of ABC proteins directly from mRNA, from cDNA, from genomic libraries or
15 cDNA libraries. Degenerate oligonucleotides can be designed to amplify ABC homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers. PCR or other in vitro amplification methods may be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of ABC protein encoding mRNA
20 in physiological samples, for nucleic acid sequencing, or for other purposes. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.

Gene expression of ABC proteins can also be analyzed by techniques known in the art, e.g., reverse transcription and amplification of mRNA, isolation of total
25 RNA or polyA⁺ RNA, northern blotting, dot blotting, in situ hybridization, RNase protection, probing DNA microchip arrays, and the like.

Synthetic oligonucleotides can be used to construct recombinant ABC genes for use as probes or for expression of protein. This method is performed using a series of overlapping oligonucleotides usually 40-120 bp in length, representing both the
30 sense and nonsense strands of the gene. These DNA fragments are then annealed, ligated and cloned. Alternatively, amplification techniques can be used with precise primers to amplify a specific subsequence of the ABC nucleic acid. The specific subsequence is then ligated into an expression vector.

The nucleic acid encoding the MXR1 protein is typically cloned into intermediate vectors before transformation into prokaryotic or eukaryotic cells for replication and/or expression. These intermediate vectors are typically prokaryote vectors, e.g., plasmids or shuttle vectors.

Expression Of ATP-Binding Cassette Proteins

To obtain high level expression of a cloned gene or nucleic acid, such as those cDNAs encoding the ABC protein MXR1, one typically subclones *MXR* into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.* and Ausubel *et al.* Bacterial expression systems for expressing MXR1 are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.

The promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the MXR1 encoding nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding an ABC protein and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. The nucleic acid sequence encoding MXR1 may typically be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell. Such signal peptides would include, among others, the signal peptides from tissue plasminogen activator, insulin, and neuron growth factor, and juvenile hormone esterase of *Heliothis virescens*. Additional

elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as GST and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., c-myc.

Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A⁺, pMTO10/A⁺, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Some expression systems have markers that provide gene amplification such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with an MXR1 encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

The elements that are typically included in expression vectors also include a replicon that functions in *E. coli*, a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. The prokaryotic sequences are preferably chosen

such that they do not interfere with the replication of the DNA in eukaryotic cells, if necessary.

Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of MXR protein, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.* 264:17619-17622 (1989); *Guide to Protein Purification*, in *Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g., Morrison, J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983).

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g., Sambrook et al., supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing MXR protein.

Another mode of expression for ABC proteins involves transactivation, which describes a method of activating (i.e., turning on) and amplifying an endogenous gene encoding a desired product, such as MXR1, in a transfected cell (*See, e.g., US Patent No. 5,733,761*).

DNA sequences that are not normally functionally linked to the endogenous gene, can be introduced by homologous recombination with genomic DNA. The DNA sequences would be inserted into the host genome at or near the endogenous gene and serve to alter (e.g., activate) the expression of the endogenous gene and further allow selection of cells in which the activated endogenous gene is amplified.

The transactivation can be used to target different events in the cell by a simple insertion of a regulatory sequence that places the endogenous gene under the control of the new regulatory sequence (for example, by insertion of either a promoter or an enhancer, both upstream of an endogenous gene). Additionally the transactivation protocols can be used to delete a regulatory element or replace an existing element. For example, a tissue specific enhancer can be replaced by an enhancer that has broader or

different cell-type specificity. In all cases, the targeting event can be identified by the use of one or more selectable markers that are physically associated with the targeting DNA sequence, allowing for selection of cells in which the exogenous DNA sequence has been integrated into the host cell genome. (*see, e.g., US Patent No. 5,733,761.*)

5 In another embodiment, the invention includes polymorphic alleles of MXR1. In addition, those of skill can readily create muteins or analogs of MXR1 based on comparisons with the mouse sequence of SEQ ID NO: 4 and conservative amino acid substitutions. When compared to SEQ ID NO: 2, a protein that exhibits conservative substitutions, as described above, is a protein of the invention. Such substitutions will
10 alter the sequence of the protein from that provided in SEQ ID NO:2, but will not markedly change the biological activity of the molecule. For example, the serine at position 519 may be changed to a threonine; the alanine at position 529 may be changed to a threonine; the isoleucine at position 550 may be changed to leucine; and the alanine at position 597 may be changed to valine. These substitutions are provided by way of
15 illustration and for clarity of understanding and not by way of limitation. It will be readily apparent to those of ordinary skill in the art, in light of the teachings of the invention, that certain changes may be made to the MXR1 protein sequence without changing its biological activity.

After the expression vector is introduced into the cells, the transfected cells
20 are cultured under conditions favoring expression of MXR1 proteins, which are recovered from the culture using standard techniques identified below.

Purification Of ATP-Binding Cassette Proteins

Once expressed the MXR1 proteins can be purified. Either naturally
25 occurring or recombinant MXR1 protein can be purified for use in functional assays. Preferably, recombinant MXR1 is purified. Naturally occurring MXR1 protein is purified, *e.g.,* from mammalian tissue such as placenta, fetal brain or liver tissues and any other source of an MXR1 homolog. Recombinant MXR1 is purified from any suitable expression system.

30 MXR1 may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (*see, e.g., Scopes, Protein*

Purification: Principles and Practice (1982); U.S. Patent No. 4,673,641; Ausubel *et al.*, *supra*; and Sambrook *et al.*, *supra*).

A number of procedures can be employed when recombinant MXR1 is being purified. For example, proteins having established molecular adhesion properties can be reversibly fused to MXR1. With the appropriate ligand, MXR1 can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. Finally, MXR1 protein could be purified using immunoaffinity columns.

A. Purification of MXR1 from recombinant bacteria

Recombinant proteins are expressed by transformed bacteria in large amounts, typically after promoter induction; but expression can be constitutive. Promoter induction with IPTG is a one example of an inducible promoter system. Bacteria are grown according to standard procedures in the art. Fresh or frozen bacteria cells are used for isolation of protein.

Proteins expressed in bacteria may form insoluble aggregates ("inclusion bodies"). Several protocols are suitable for purification of MXR1 inclusion bodies. For example, purification of inclusion bodies typically involves the extraction, separation and/or purification of inclusion bodies by disruption of bacterial cells, e.g., by incubation in a buffer of 50 mM TRIS/HCL pH 7.5, 50 mM NaCl, 5 mM $MgCl_2$, 1 mM DTT, 0.1 mM ATP, and 1 mM PMSF. The cell suspension can be lysed using 2-3 passages through a French Press, homogenized using a Polytron (Brinkman Instruments) or sonicated on ice. Alternate methods of lysing bacteria are apparent to those of skill in the art (*see, e.g., Sambrook et al., supra; Ausubel et al., supra*).

If necessary, the inclusion bodies are solubilized, and the lysed cell suspension is typically centrifuged to remove unwanted insoluble matter. Proteins that formed the inclusion bodies may be renatured by dilution or dialysis with a compatible buffer. Suitable solvents include, but are not limited to urea (from about 4 M to about 8 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to about 8 M). Some solvents which are capable of solubilizing aggregate-forming proteins, for example SDS (sodium dodecyl sulfate), 70% formic acid, are inappropriate for use in this procedure due to the possibility of irreversible denaturation of the proteins, accompanied by a lack of immunogenicity and/or activity. Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of immunologically and/or biologically active protein. Other suitable buffers are known to those skilled in the art. MXR1 is separated from other bacterial proteins by standard separation techniques, e.g., with Ni-NTA agarose resin.

Alternatively, it is possible to purify MXR1 protein from bacteria periplasm. After lysis of the bacteria, when MXR1 is exported into the periplasm of the bacteria, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to those of skill in the art. To isolate recombinant proteins from the periplasm, the bacterial cells are centrifuged to form a pellet. The pellet is resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria are centrifuged and the pellet is resuspended in ice-cold 5 mM MgSO₄ and kept in an ice bath for approximately 10 minutes. The cell suspension is centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well known to those of skill in the art.

B. Standard Protein Separation Techniques For Purifying MXR1
Solubility Fractionation

Often as an initial step, particularly if the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. The preferred salt is ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

Size Differential Filtration

The molecular weight of MXR1 can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.

Column Chromatography

MXR1 can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).

Antisense Applications For ATP-Binding Cassette Proteins

Gene regulation in *MXR1* can be downregulated or entirely inhibited by the use of antisense molecules. An "antisense sequence or antisense nucleic acid" is a nucleic acid that is complementary to the coding *MXR1* mRNA nucleic acid sequence or a subsequence thereof. Binding of the antisense molecule to the *MXR1* mRNA interferes with normal translation of *MXR1*. The antisense molecule can be an endogenous or an exogenous complement to an mRNA. It can also be ribozyme or a ribozyme combined with a mRNA complement.

In conventional antisense technology, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter sequence such that the antisense strand of RNA will be transcribed. The construct is then transformed into cells and the anti-sense strand of RNA is produced. (see, e.g., Sheehy et al., Proc. Nat. Acad. Sci. USA 85:8805-8809 (1988), and Hiatt, et al., U.S. Pat. No. 4,801,340.)

The nucleic acid segment to be introduced in antisense suppression generally will be substantially identical to at least a portion of the endogenous gene or gene to be repressed, but need not be identical. The vectors can thus be designed such that the inhibitory effect applies to other proteins within a family of genes exhibiting homology or substantial homology to the target gene. The introduced sequence also need not be full length relative to either the primary transcription product or fully processed mRNA. Generally, higher homology can be used to compensate for the use of a shorter sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and homology of non-coding segments will be equally effective.

Absolute complementarity of the antisense molecule, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein,

means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation than oligonucleotides that are complementary to 5'- or 3'- untranslated sequence, but should be used in accordance with the instant invention. The antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects, the oligonucleotide is at least 10 nucleotides, preferably at least 17 nucleotides, more preferably at least 25 nucleotides or most preferably at least 50 nucleotides.

Thus, in accordance with preferred embodiments of this invention, preferred antisense molecules include oligonucleotides and oligonucleotide analogs that are hybridizable with *MXR1* mRNA. This relationship is commonly denominated as "antisense." The oligonucleotides and oligonucleotide analogs are able to inhibit the function of the RNA, either its translation into protein, its translocation into the cytoplasm, or any other activity necessary to its overall biological function. The failure of the messenger RNA to perform all or part of its function results in a reduction or complete inhibition of expression of *MXR* polypeptides.

The mechanisms above also work with exogenous antisense molecules that are modified to be nuclease resistant. Therefore, in the context of this invention, the term "oligonucleotide" refers to a polynucleotide formed from naturally-occurring bases and/or cyclofuranosyl groups joined by native phosphodiester bonds. This term effectively refers to naturally-occurring species or synthetic species formed from naturally-occurring subunits or their close homologs. The term "oligonucleotide" may also refer to moieties which function similarly to oligonucleotides, but which have non naturally-occurring portions. Thus, oligonucleotides may have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. In accordance with some preferred embodiments, at

least one of the phosphodiester bonds of the oligonucleotide has been substituted with a structure which functions to enhance the ability of the compositions to penetrate into the region of cells where the RNA whose activity is to be modulated is located. It is preferred that such substitutions comprise phosphorothioate bonds, methyl phosphonate bonds, or short chain alkyl or cycloalkyl structures. In accordance with other preferred 5 embodiments, the phosphodiester bonds are substituted with structures which are, at once, substantially non-ionic and non-chiral, or with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in the practice of the invention.

10 Oligonucleotides may also include species which include at least some modified base forms. Thus, purines and pyrimidines other than those normally found in nature may be so employed. Similarly, modifications on the furanosyl portions of the nucleotide subunits may also be effected, as long as the essential tenets of this invention are adhered to. Examples of such modifications are 2'-O-alkyl- and 2'-halogen- 15 substituted nucleotides. Some specific examples of modifications at the 2' position of sugar moieties which are useful in the present invention are OH, SH, SCH₃, F, OCH₃, OCN, O(CH₂)[n]NH₂ or O(CH₂)[n]CH₃, where n is from 1 to about 10, and other substituents having similar properties.

Such oligonucleotides are best described as being functionally 20 interchangeable with natural oligonucleotides or synthesized oligonucleotides along natural lines, but which have one or more differences from natural structure. All such analogs are comprehended by this invention so long as they function effectively to hybridize with messenger RNA of MXR1 to inhibit the function of that RNA.

The oligonucleotides in accordance with this invention preferably 25 comprise from about 3 to about 50 subunits. It is more preferred that such oligonucleotides and analogs comprise from about 8 to about 25 subunits and still more preferred to have from about 12 to about 20 subunits. As will be appreciated, a subunit is a base and sugar combination suitably bound to adjacent subunits through phosphodiester or other bonds. The oligonucleotides used in accordance with this invention may be 30 conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. Any other means for such synthesis may also be employed, however, the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is

also will known to prepare other oligonucleotide such as phosphorothioates and alkylated derivatives.

Catalytic RNA molecules or ribozymes can be used as a means to inhibit expression of endogenous genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. Ribozymes include but are not limited to any of the various types, such as hairpin or hammerhead ribozymes. The design and use of target RNA-specific ribozymes is described in Haseloff et al., *Nature*, 334:585-591 (1988).

Antibodies Binding ATP-Binding Cassette Proteins

Methods of producing polyclonal and monoclonal antibodies that react specifically with MXR1 are known to those of skill in the art. *See, e.g.*, Coligan (1991), *CURRENT PROTOCOLS IN IMMUNOLOGY*, Wiley/Greene, NY; and Harlow and Lane; Stites et al. (eds.) *BASIC AND CLINICAL IMMUNOLOGY* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986), *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE* (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975), *Nature*, 256:495-497. Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors. *See*, Huse et al. (1989), *Science*, 246:1275-1281; and Ward et al. (1989), *Nature*, 341:544-546. For example, in order to produce antisera for use in an immunoassay, the ATP binding cassette polypeptide partially encoded by SEQ ID NO: 1 or 3 or a fragment thereof, is isolated as described herein. For example, recombinant protein is produced in a transformed cell line. An inbred strain of mice or rabbits is immunized with the protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen. Polyclonal sera are collected and titrated against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross

reactivity against non-ATP binding cassette protein, MXR1, or even other homologous proteins from other organisms, using a competitive binding immunoassay. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a K_D of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better.

A number of MXR1 comprising immunogens may be used to produce antibodies specifically reactive with MXR1. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Naturally occurring protein may also be used either in pure or impure form. Synthetic peptides made using the protein sequences described herein may also be used as an immunogen for the production of antibodies to the protein. Recombinant protein can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those of skill in the art. In brief, an immunogen, preferably a purified protein, is mixed with an adjuvant and animals are immunized. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the ATP binding cassette protein, MXR1. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired. (*See Harlow and Lane, supra*).

Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (*See, Kohler and Milstein, Eur. J. Immunol.* 6:511-519 (1976), incorporated herein by reference). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences

which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse, *et al.* (1989) *Science* 246:1275-1281.

Other suitable techniques involve selection of libraries of recombinant antibodies in phage or similar vectors (*see, e.g.,* Huse *et al.* (1989) *Science* 246: 1275-1281; and Ward, *et al.* (1989) *Nature* 341: 544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14: 309-314).

Single chain recombinant versions of antibodies, against predetermined fragments of ABC polypeptides, such as MXR1, are raised by immunizing animals, *e.g.,* with conjugates of the fragments with carrier proteins as described above. Typically, the immunogen of interest is a peptide of at least about 5 amino acids, more typically the peptide is 10 amino acids in length, preferably, the fragment is 15 amino acids in length and more preferably the fragment is 20 amino acids in length or greater. The peptides are typically coupled to a carrier protein (*e.g.,* as a fusion protein), or are recombinantly expressed in an immunization vector. Antigenic determinants on peptides to which antibodies bind are typically 3 to 10 amino acids in length.

Once specific antibodies are available, a particular protein, such as MXR1, can be detected by a variety of immunoassay methods. For a review of immunological and immunoassay procedures in general, see *Basic and Clinical Immunology* 7th Edition (D. Stites and A. Terr ed.) 1991. Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay*, E.T. Maggio, ed., CRC Press, Boca Raton, Florida (1980); "Practice and Theory of Enzyme Immunoassays," Tijssen; and, Harlow and Lane, each of which is incorporated herein by reference.

Immunoassays to ATP binding cassette protein MXR1 of the present invention may use a polyclonal antiserum which was raised to the protein partially encoded by SEQ ID NO: 1, or a fragment thereof. This antiserum is selected to have low crossreactivity against other non-ATP binding cassette proteins and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay.

In order to produce antisera for use in an immunoassay, the ATP binding cassette protein of this invention or a fragment thereof, is isolated as described herein. For example, recombinant protein is produced in a transformed cell line. An inbred strain of mice such as Balb/c is immunized with the protein or a peptide using a standard

adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against non-MXR1 ABC proteins, such as the human white gene homolog (see, e.g., Croop, J.M. et al. Gene (1997) 185 (1):77-85) using a competitive binding immunoassay such as the one described in Harlow and Lane, *supra*, at pages 570-573 and below.

Immunological Binding Assays.

In a preferred embodiment, the ATP binding cassette protein is detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology Volume 37: Antibodies in Cell Biology*, Asai, ed. Academic Press, Inc. New York (1993); *Basic and Clinical Immunology* 7th Edition, Stites & Terr, eds. (1991). Immunological binding assays (or immunoassays) typically utilize a "capture agent" to specifically bind to and often immobilize the analyte (in this case the ATP binding cassette protein or subsequence). The capture agent is a moiety that specifically binds to the analyte. In a preferred embodiment, the capture agent is an antibody that specifically binds the ATP binding cassette protein. The antibody (anti-ABC protein MXR1) may be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte. The labeling agent may itself be one of the moieties comprising the antibody/analyte complex. Thus, the labeling agent may be a labeled ATP binding cassette polypeptide or a labeled anti-ATP binding cassette antibody. Alternatively, the labeling agent may be a third moiety, such as another antibody, that specifically binds to the antibody/ATP binding cassette complex.

In a preferred embodiment, the labeling agent is a second human ATP binding cassette antibody bearing a label. Alternatively, the second antibody may lack a

label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

5 Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins are normal constituents of the cell walls of streptococcal bacteria. They exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, generally Kronval, *et al.* (1973) *J. Immunol.*, 111: 1401-1406, and
10 Akerstrom, *et al.* (1985) *J. Immunol.*, 135: 2589-2542).

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, analyte, volume of solution,
15 concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

Competitive assay formats.

20 In competitive assays, the amount of analyte (ATP binding cassette protein) present in the sample is measured indirectly by measuring the amount of an added (exogenous) analyte (i.e., the ATP binding cassette protein) displaced (or competed away) from a capture agent (anti ABC antibody) by the analyte present in the sample. In one competitive assay, a known amount of, in this case, the ATP binding cassette protein,
25 MXR1 is added to the sample and the sample is then contacted with a capture agent, in this case an antibody that specifically binds to MXR1. The amount of MXR1 bound to the antibody is inversely proportional to the concentration of MXR1 present in the sample.

30 In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of the MXR1 bound to the antibody may be determined either by measuring the amount of MXR1 present in an MXR1/antibody complex, or

alternatively by measuring the amount of remaining uncomplexed protein. The amount of MXR1 protein may be detected by providing a labeled MXR1 molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay a known analyte, in this case the ATP binding cassette protein, MXR1 is
5 immobilized on a solid substrate. A known amount of anti-MXR1 antibody is added to the sample, and the sample is then contacted with the immobilized MXR1. In this case, the amount of anti-MXR1 antibody bound to the immobilized MXR1 is inversely
10 proportional to the amount of MXR1 present in the sample. Again the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

Immunoassays in the competitive binding format can be used for crossreactivity determinations. For example, the protein of SEQ ID NO:2 can be
15 immobilized to a solid support. Proteins are added to the assay which compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the protein partially encoded by SEQ ID NO:1 or 3. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10%
20 crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the above-listed proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, such as human
25 white homolog, (GenBank # U34919) to the immunogen protein (i.e., MXR1 of SEQ ID NO: 2). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of protein required is less than twice the amount of the protein encoded by SEQ ID NO: 2, then the
30 second protein is said to specifically bind to an antibody generated to the MXR1 immunogen.

In addition to using nucleic acid probes for identifying novel forms of the protein claimed herein, it is possible to use antibodies to probe expression libraries. This

is a well known technology. (See Young and Davis, 1982 Efficient isolation of genes using antibody probes *Proc. Natl. Acad. Sci., U.S.A.* 80:1194-1198.) In general, a cDNA expression library maybe prepared from commercially available kits or using readily available components. Phage vectors are preferred, but a variety of other vectors are available for the expression of protein. such vectors include but are not limited to yeast, animal cells and *Xenopus* oocytes. One selects mRNA from a source that is enriched with the target protein and creates cDNA which is then ligated into a vector and transformed into the library host cells for immunoscreening. Screening involves binding and visualization of antibodies bound to specific proteins on cells or immobilized on a solid support such as nitrocellulose or nylon membranes. Positive clones are selected for purification to homogeneity and the isolated cDNA then prepared for expression in the desired host cells. A good general review of this technology can be found in *Methods of Cell Biology* Vol 37 entitled Antibodies in Cell Biology, Ed. DJ Asai pp 369-382, 1993.

Where the antibodies are generated to a a short peptide, the test proteins are optionally denatured to fully test for selective binding and it may be best to measure the test proteins are against proteins of similar size, e.g., one would test a full length monomer against a prototype full length monomer even though the antisera was generated against a peptide of the prototype monomer. This simplifies the test and avoids having to take into account conformational problems and molecular weight/molar concentrations in the determination of the results from the competitive immunoassays.

Assays for detecting ATP-binding cassette protein activity and for identification of inhibitors of ATP-binding cassette proteins.

Cells that overexpress ABC proteins (ABCP) have been shown to be resistant to several chemotherapy drugs. These include mitoxantrone, several anthracyclines, rhodamine, daunomycin, SN-38 (the active metabolite of CPT-11), topotecan, and bisantrene. To identify compounds that can reverse the effect of ABCP overexpression, the concentration of drug that inhibits the proliferation of resistant cells by 50 % (IC₅₀) can be measured by an assay in the presence and absence of putative inhibitors. Compounds that cause a significant decrease in the IC₅₀ will represent inhibitors and be characterized further.

The assay involves screening for inhibitors of mitoxantrone resistance in cells that overexpress the MXR1 protein, such as S1-M1-80 cells, MCF-7 AdVp3000

cells, or MCF-7 MX100 cells. (see, e.g., Lee et al., J. Cell. Biochem. 65(4):513-526 (1997)) The cells used can be genetically altered cells that have been altered to overexpress the ATP protein.

The cells can be cultured under standard culture conditions, such as those used in Scala et al., (1997) Mol. Pharmacol. 51(6) 1024-33, for MDR or those conditions used in Lee et al., J. Cell. Biochem. 65(4):513-526 (1997), for MCF-7 AdVp3000.

The cells are then contacted with a toxic chemotherapy drug, such as mitoxantrone or daunomycin, in an amount that permits cell survival due to the resistance conferred by the ATP-binding cassette protein. The amount used is preferably from about 30 μ M to about 3 mM. The cells are exposed to the drug for a time that is preferably from about 48 hours to about 96 hours. Cell growth is measured for these cells based on sulforhodamine staining measurement. Alternatively, cell growth can be monitored by vital stains, metabolite measurements or counting cell divisions.

One specific way to measure cell viability is by a colorimetric assay (Skehan et al., Natl. Cancer Inst. 82: 1117-1121 (1990)). Cells can be seeded in 96-well plates at 1000 cells/well, grown for 4 days, and fixed in 50% trichloroacetic acid for example. The cells can then be stained in 0.4% sulphorhodamine B dissolved in 1% acetic acid. After washing, the bound dye can be solubilized with 10 nM unbuffered Tris base, preferably at pH 10.5. The number of viable cells can then be determined by measuring the OD at 570 nm. Alternatively, viability of cells can be measured by counting cells with a cell counter or by incorporation of tritiated thymidine.

The cells are then contacted with a compound that inhibits the biological activity of the ATP-binding cassette protein. Examples of such an inhibitor include, but are not limited to, drugs identified as chemosensitizers which are able to restore sensitivity to cytotoxic agents by inhibiting the transport of P-gP substrates. These include, but are not limited to, calcium channel antagonists, antiarrhythmics, antihypertensives, diterpenes, cyclosporines, and many others. The potential inhibitor would be applied to the cell in an amount from about 1 μ M to about 1 mM, for a time between about 48 and about 72 hours.

The inhibition of drug resistance can then be detected by measuring the growth inhibition of cells, using a variety of means, such as IC50 measurements, vital

staining, metabolite measurements, or confocal microscopy. Confocal microscopy can be used to determine whether a particular drug has been retained or accumulated in the cell.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of noncritical parameters which could be changed or modified to yield essentially similar results.

Example 1. Cloning of ATP-binding cassette protein MXR1.

cDNA libraries constructed with the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (GIBCO-BRL, Rockville MD) using mRNA from mitoxantrone resistant S1-M1-80 human colon carcinoma cells can be used to isolate the MXR1 and MXR2 nucleic acids of the invention.

The ABC protein (ABCP) gene can be isolated using primers that flank the coding region of the gene. These primers can be used to amplify cDNA reverse transcribed from placenta RNA. Primers corresponding to SEQ ID NO: 5 or 6 can be used to amplify by PCR a 2284 bp product from placenta cDNA. This product can be cloned into the pGEM-T (Promega Madison, WI) vector. The sequence of the clone can be confirmed by DNA sequencing of the clone using the original primers as well as 20 nucleotide primers, 300 bp apart, along the coding region of the ABCP gene.

Example 2. Expression of ATP-binding cassette protein MXR1.

5 The coding region of the MXR1 gene can be cloned into appropriate expression vectors to express the gene in cells. This could be for the purpose of purifying the protein to study its properties or raise antibodies, or to study the properties of the protein overexpressed in a mammalian cell line. The full length coding region of MXR1 can be cloned in the N-terminal to C-terminal orientation into the pBacPAK8 transfer
10 vector (Clontech, Palo Alto, CA) vector to express the protein in insect cell cultures. Alternatively the MXR1 gene can be cloned into the pNeoEGFP vector (Clontech, Palo Alto, CA) to express the protein in mammalian cells. The expression of the protein can be monitored by tagging the amino or carboxy terminus with an appropriate tag (GFP, his) or the untagged protein can be monitored using polyclonal or monoclonal antiserum
15 specific for the MXR1 protein. The nucleotide and amino acid sequences of MXR1 are provided, respectively, in SEQ ID NO:1 and 3 and SEQ ID NO:2 and 4.

Example 3. Assay for identification of inhibitors of mitoxantrone resistance.

20 The cells that overexpress MXR1 have been shown to be resistant to several chemotherapy drugs. These include mitoxantrone, several anthracyclines, rhodamine, daunomycin, SN-38 (the active metabolite of CPT-11), topotecan, and bisantrene. To identify compounds that can reverse the effect of MXR1 overexpression, the concentration of drug that inhibits the proliferation of resistant cells by 50 % (IC₅₀)
25 will be measured in the presence and absence of putative inhibitors. Compounds that cause a significant decrease in the IC₅₀ will represent inhibitors and be characterized further. For example, S1-M1-80 cells can be incubated in media containing 30 micromolar (IC₁₀) of mitoxantrone and the proliferation of the cells measured by sulforhodamine staining after 96 hours with and without the addition of various potential
30 inhibitors, as a screening assay. Next, for compounds that have potential activity, a formal calculation of the IC₅₀ can be made by incubating the cells in a range of concentrations, diluting 3-fold from 3 mM, again, with and without the inhibitor in question. From this

data the IC50 can be calculated. In the absence of a reversal agent, the IC50 is 100 micromolar for the S1M1-80 cells. Compounds that lower the IC50 for mitoxantrone can be tested for their ability to also lower the IC50 for other MXR1-transporting drugs such as adriamycin, topotecan, or bisantrene.

5 As a preliminary screening assay, we can also evaluate the alteration in accumulation of mitoxantrone by confocal microscopy, or of rhodamine by FACS analysis. The latter assay, popularized by investigators working with Pgp antagonists has been used as a screening tool (*see, e.g.,* Scala, et al., Mol. Pharmacol (1997) 51(6):1024-33). Drug resistant cells are obtained from tissue culture dishes, plated into each well of a
10 96 well plate and then incubated in 1 mM rhodamine 123. Candidate inhibitors are added 15 minutes before addition of the rhodamine. Cells are then incubated for 1 hour, washed and then resuspended for an efflux period in medium alone, or medium containing the candidate inhibitor. After 30 minutes, the level of rhodamine remaining in the cells is tightly correlated with the inhibition of the transporter. A positive control using energy
15 depletion can be incorporated into this study.

Analysis of mitoxantrone accumulation by confocal microscopy is very straightforward and simple assay, which requires no preincubation. The experiment can be performed literally under the microscope, and a 15 minute accumulation of mitoxantrone obtained. The confocal microscope can be set at a specific sensitivity, and
20 thus quantitative information gathered when the accumulation is performed in the presence and absence of the inhibitor.

A NOVEL ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN RESISTANCE

REFERENCE 1 (bases 1 to 2719)

AUTHORS Allikmets,R., Gerrard,B., Hutchinson,A. and Dean,M.

TITLE Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database

JOURNAL Human Molecular Genetics 5, 1649-1655 (1996)

REFERENCE 2 (bases 1 to 2719)

AUTHORS Allikmets,R., Schriml,L.M., Hutchinson,A., Romano-Spica,V. and Dean,M.

TITLE A Human Placenta-Specific ATP-Binding Cassette Gene (ABCP) on Chromosome 4q22 that is Involved in Multidrug Resistance

JOURNAL Cancer Research 58 (1998) In press

SEQ ID NO: 1

BASE COUNT 799 a 545 c 564 g 811 t

ORIGIN

1 tttagaacg caccgtgcac atgcttggtg gtcttgtaa gtggaaactg ctgctttaga
61 gttgttttg aaggtcggg tgactcatcc caacatttac atccttaatt gttaaagcgc
121 tgctccgag cgcacgcac ctgagatcct gagccttttg ttaagaccga gctctattaa
181 gctgaaaaga taaaaactct ccagatgtct tcagtaaatg tcgaagtgtt tatcccaagt
241 tcacaaggaa acaccaatgg ctccccgcg acagtttcca atgacctgaa ggcattactg
301 gaaggagctg tgttaagttt tcataacatc tgctatcgag taaaactgaa gagtggcttt
361 ctacctgtc gaaaaccagt tgagaaagaa atattatcga atatcaatgg gatcatgaaa
421 cctgggtcga acgccatcct gggaccacca ggtggaggca aatcttcgtt attagatgtc
481 ttactgtcaa ggaaagatcc aagtggatta tctggagatg ttctgataaa tggagcaccg
541 cgacctgcca atttcaaatg taattcaggt tacgtgtgac aagatgatgt tgtgatgggc
601 actctgacgg tgagagaaaa ctacagttc tcagcagctc ttcggttgc aacaactatg
661 acgaatcatg aaaaaaacga acggattaac agggtcattg aagagttagg tctgtataaa
721 gtggcagact ccaaggttgg aactcagttt atccgttggt tgtctggagg agaagaaaa
781 aggactagta taggaatgga gcttaactac gatacttoca tctgtcctt ggaatgacct
841 acaactggct tagactcaag cacagcaaat gctgtccttt tgctctgtaa aaggatgtct
901 aagcagggac gaacaatcat ctctccatt catcagctc gatattocat cttaagttg

A NOVEL ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN
RESISTANCE

961 ttgatagcc tcacctatt ggcctcagga agacttatgt tccacgggcc tgctcaggag
1021 gccttgggat actttgaatc agctggttat cactgtgagg cctataataa cctgcagac
1081 ttctcttgg acatcattaa tggagattcc actgctgttg cattaacag agaagaagac
1141 tttaaagcca cagagatcat agagccttcc aagcaggata agccactcat agaaaaatta
1201 gcggagattt atgtcaactc ctctcttctc aaagagacaa aagctgaatt acatcaactt
1261 tccgggggtg agaagaagaa gaagatcaca gtcttcaagg agatcageta caccacctcc
1321 ttctgtcatc aactcagatg ggtttccaag cggttcattca aaaacttgtc gggtaatccc
1381 caggcctcta tagctcagat cattgtcaca gtctactgg gactgggtat aggtgccatt
1441 tactttgggc taaaaaatga ttctactgga atccagaaca gagctggggt tctcttcttc
1501 ctgacgacca accagtgttt cagcagtgtt tcagccgttg aactctttgt ggtagagaag
1561 aagctcttca tacatgaata catcagcggg tactacagag tgtcatctta ttctcttgga
1621 aaactgttat ctgatttatt acccatgagg atgttacaa gtattattat tactgtata
1681 gtgtacttca tgttaggatt gaagccaaag gcagatgcct tcttcgttat gatgtttacc
1741 ctatgatagg tggctatttc agccagtcc atggcactgg ccatagcagc aggtcagagt
1801 gtgtttctg tagcaacct tctcatgacc atctgttttg tgttatgat gatttttca
1861 ggtctgttg tcaatctcac aaccattgca tcttgctgt catgcttca gtacttcagc
1921 attccacgat atggatttac ggctttgcag cataatgaat ttttggaca aaactctgc
1981 ccaggactca atgcaacagg aaacaatcct tghtaatatg caacatgtac tggcgaagaa
2041 tatttggtaa agcaggggcat cgtatcttca cctcggggct tgttgaagaa tcacgtggcc
2101 ttgcttgta tgattgttat ttctctcaca attgccatcc tgaattgtt atttctaaa
2161 aaatattctt aaatttccc ttaattcagt atgatttacc ctacataaa aaagaagcac
2221 ttgattgaa gtatcaatc aagtttttt gttgtttct gtcccttgc catcacactg
2281 ttgcacagca gcaattgttt taaagagata catttttaga aatcacaaca aactgaatta
2341 aacatgaaag aaccaagac atcatgtatc gcatattagt taatctctc agacagtaac
2401 catggggaag aaatctgttc taatttatta atctaaaaaa ggagaattga attctgaaa
2461 ctctgacaa gttattactg tctctggcat ttgtttcttc atcttataaa tgaataggta
2521 ggttagtagc ccttcagict taatacttta tgatgctatg gtttccatt atttaataa
2581 tgacaaatgt attaatgcta tactggaaat gtaaaatga aaatatgttg gaaaaaagat
2641 tctgtcttat agggtaaaaa aagccaccgg tgaatagaaa aaaatctttt tgataagcac
2701 attaaagtta atagaactt

SEQ ID NO: 2

005637.001901

A NOVEL ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN
RESISTANCE

/translation="MSSSNVEVFIPVSQGNTNGFPATVSNDLKAFTEGAVLSFHNICY
RVKLKSGFLPCRKPVEKEILSNINGIMKPLNAILGPTGGGKSSLLDVLAARKDPS
GLSGDVLINGAPRPANFKCNSGYVVQDDVVMGTLTVRENLQFSAALRLATTMT
NHEKNERINRVIEELGLDKVADSKVGTQFIRGVSGGERKRTSIGMELITDPSILSLD
EPTTGLDSSSTANAVLLLLKRMSKQGRTHFSIHQPRYSIFKLFDSTLLASGRMLMFH
GPAQEALGYFESAGYHCEAYNNPADFFLDIINGDSTAVALNREEDFKATEIIEPSK
QDKPLIEKLAIEIYVNSSFYKETKAELHQLSGGEKKKKITVFKEISYTTSFCHQLRW
VSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFLKNDSTGHIQNRAGVLFLLTNN
QCFSVSAVELFVVEKKLFIHEYISGYRYVSSYFLGKLLSDLLPMRMLPSIIFTCIV
YFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLLMTICFV
FMMIFSGLLVNLTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFPCPLNATGNN
PCNYATCTGEEYLVKQGDIDSPWGLWKNHVALACMIVIFLTIAYLKLFLKKYS"

SEQ ID NO: 3

BASE COUNT 123 a 109 c 108 g 162 t

ORIGIN

1 ttggccctag gggccgagcc ttatcgccc agttccatgg cactggccat agccacagcc
61 caaagtgtgg tgtctgtagc aacactactc atgacaatcg cttttgtatt tatgatgctc
121 ttttcggccc tcttggtgaa tctcagaacc atggggccct ggctgtcctg gcttcagtac
181 tttagcattc ctcgatatgg cttcacagct ttgcagtata atgaattctt gggacaagag
241 ttttgcagc gattcaatgt aacggacaac agcacttgtg ttaacagcta tgcaatatgt
301 actggttaac agtacttgat aaatcagggc atcgaaactgt cacctggggc actgtggaag
361 aatcatgtgg ccttggtctg tatgattatt atctctcca caattgcta cctgaaattg
421 ttgttcttta aaaagtattc ttaattccc cttaacgga ctattaatg tactccaatt
481 aaatatgggc actttgatta cc

SEQ ID NO: 4

/translation="FGLGAEAYTASSMALAIATGQSVVSVATLLMTIAFVFMMLFSGL
LVNLRITGPWLSWLQYFSIPRYGFTALQYNEFLGQEFPCGFNVTDNSTCVNSYAIC
TGNEYLINQGIELSPWGLWKNHVALACMIIFLTIAYLKLFLKKYS"

0955697.091901

A NOVEL ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN
RESISTANCE

Primer sequences

SEQ ID NO: 5 ABCPF1 (5' ACGCACCGTGACATGCTTG)

SEQ ID NO: 6 ABCPR1 (5' ACAGTGTGATGGCAAGGGAACAG)

WHAT IS CLAIMED IS:

1. An isolated ATP-binding cassette protein having the following properties:
 - i. conferring mitoxantrone resistance to a S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
 - ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in Seq. ID. No. 2 or ID. No. 4; and
 - iii. having a molecular weight between about 70 kDa and about 75 kDa.
2. The ATP-binding cassette protein of claim 1 wherein the protein has 95% identity to the amino acids depicted in Seq. ID. No. 2 or ID. No. 4.
3. A eukaryote cell genetically altered to overexpress an ATP-binding cassette protein having the following properties:
 - i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,
 - ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in Seq. ID. No. 2 or ID. No. 4.
4. A cell of claim 3, wherein the cell is genetically altered by transformation of the cell with an exogenous DNA comprising an expression cassette encoding the ATP-binding cassette protein.
5. A cell of claim 4, wherein the expression cassette comprises a heterologous promoter operatively linked to the DNA encoding the ATP-binding cassette protein.
6. A cell of claim 3, wherein the cell has an endogenous copy of the ATP-binding cassette protein and the genetic alteration comprises insertion of DNA which can serve as an enhancing element or as a second promoter where the insertion is upstream of the endogenous promoter operatively linked to the ATP-binding cassette protein and where the inserted DNA increases the basal expression levels of ATP-binding cassette protein.

1 7. A DNA encoding a ATP-binding cassette protein wherein the
2 protein is characterized by having the following properties:

3 i. conferring mitoxantrone resistance on S1-M1-80 human colon
4 carcinoma cells when expressed in the cells; and,

5 ii. specifically binding to polyclonal antibodies which specifically
6 bind to a member of the group of proteins consisting of those depicted in Seq. ID. No. 2
7 or ID. No. 4.

1 8. The DNA of claim 7, wherein the encoded protein has 95% identity
2 to the amino acids depicted in Seq. ID. No. 2 or ID. No. 4.

1 9. The DNA of claim 7, wherein the DNA encoding the protein has a
2 sequence identical to that depicted in Seq. ID. No. 1 or No. 3.

1 10. A process for over expressing ATP-binding cassette protein in a
2 cell comprising a first step of either:

3 i. transforming the cell with an expression cassette which directs the
4 expression of ATP-binding cassette protein; or,

5 ii. selecting a cell having an endogenous copy of the ATP-binding
6 cassette protein, and transforming the cell with DNA which can serve as an enhancing
7 element or as a second promoter where the insertion is upstream of the endogenous
8 promoter operatively linked to the ATP-binding cassette protein and where the inserted
9 DNA increases the basal expression levels of ATP-binding cassette protein; and a second
10 step of,

11 culturing the transformed cell under conditions where the levels of
12 ATP-binding cassette protein are increased above the basal levels of the non-
13 transformed cells with the proviso that the ATP-binding cassette protein has the
14 following properties:

15 a. confers mitoxantrone resistance on S1-M1-80 human colon
16 carcinoma cells when expressed in the cells; and,

17 b. specifically binds to polyclonal antibodies which
18 specifically bind to a member of the group of proteins depicted in Seq. ID. No. 2
19 or ID. No. 4.

11. The process of claim 10, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in Seq. ID. No. 2 or ID. No. 4.

12. The process of claim 10, wherein the protein has the amino acids depicted in Seq. ID. No. 2 or ID. No. 4.

13. A method of screening for inhibitors of cytotoxin resistance in cells comprising the steps of:

(a) culturing a cell genetically altered by the introduction of heterologous DNA which permits the overexpression an ATP-binding cassette protein where the protein has the following properties:

i. conferring mitoxantrone resistance on S1-M1-80 human colon carcinoma cells when expressed in the cells; and,

ii. specifically binding to polyclonal antibodies which specifically bind to a member of the group of proteins depicted in Seq. ID. No. 2 or ID. No. 4;

(b) contacting the cell with a cytotoxin in an amount that permits cell survival due to the resistance conferred by the ATP-binding cassette protein;

(c) contacting the cell with a compound that inhibits the biological activity of the ATP-binding cassette protein;

(d) detecting the inhibition by measuring growth inhibition of the cells.

14. A method of claim 13, where the cytotoxin is mitoxantrone.

15. A method of claim 13, where the cytotoxin is daunomycin.

16. A method of claim 13, where the cell is a carcinoma cell.

17. A method of claim 13, wherein the ATP-binding cassette protein has 95% homology to the amino acids depicted in Seq. ID. No. 2 or ID. No. 4.

18. A binding protein which specifically binds to an ATP-binding cassette protein which has 95% homology to the amino acids depicted in Seq. ID. No. 2 or ID. No. 4.

1 19. A binding protein of claim 18, wherein the binding protein is an
2 antibody.

1 20. A binding protein of claim 18, wherein the binding protein is a
2 monoclonal antibody.

SF 180537 v1

09856927.091901

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: AN ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN RESISTANCE, the specification of which was filed on 24 November 1999 as PCT International Application No. PCT/US99/28107, and which received U.S. Serial Number 09/856,927.

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes <input type="checkbox"/> No <input type="checkbox"/>
			Yes <input type="checkbox"/> No <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/110,473	30 November 1998

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) of the Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Office of Technology Transfer, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.


Robert Benson, Reg. No. 33,612
Steven M. Ferguson, Reg. No. 38,448
James C. Haight, Reg. No. 25,588
John P. Kim, Reg. No. 38,514

Susan S. Rucker, Reg. No. 35,762
David R. Sadowski, Reg. No. 32,808
Jack Spiegel, Reg. No. 34,477

Send Correspondence to Appointed Associate Attorney or Agent Address: <u>Kenneth A. Weber</u> TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834	Direct Telephone Calls and Facsimiles to Appointed Associate Attorney or Agent: Name: Kenneth A. Weber Reg. No.: 31,667 Telephone: 415/576-0200 Fax: 415/576-0300
---	---

Full Name of Inventor 1	Last Name <u>Dean</u>	First Name <u>Michael</u>	Middle Name or Initial	
Residence & Citizenship	City <u>Frederick</u>	State/Foreign Country Maryland <u>MD</u>	Country of Citizenship US	
Post Office Address	Post Office Address 1362 Hitchingpost Lane	City Frederick	State/Country Maryland	Zip Code 21703
Full Name of Inventor 2	Last Name <u>Allikmets</u>	First Name <u>Rando</u>	Middle Name or Initial <u>L</u>	
Residence & Citizenship	City <u>Cornwall-on-the-Hudson</u>	State/Foreign Country New York <u>NY</u>	Country of Citizenship EE	
Post Office Address	Post Office Address 90 Maple Road	City Cornwall-on-the-Hudson	State/Country New York	Zip Code 12520
Full Name of Inventor 3	Last Name <u>Bates</u>	First Name <u>Susan</u>	Middle Name or Initial <u>E</u>	
Residence & Citizenship	City <u>Bethesda</u>	State/Foreign Country Maryland <u>MD</u>	Country of Citizenship US	
Post Office Address	Post Office Address 5402 Alta Vista Road	City Bethesda	State/Country Maryland	Zip Code 20814
Full Name of Inventor 4	Last Name <u>Fojo</u>	First Name <u>Antonio</u>	Middle Name or Initial <u>T</u>	
Residence & Citizenship	City <u>Rockville</u>	State/Foreign Country Maryland <u>MD</u>	Country of Citizenship US	
Post Office Address	Post Office Address 18 New Mark Esplanade	City Rockville	State/Country Maryland	Zip Code 20850


I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the United States Code, Section 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  5/28/01	Signature of Inventor 2	Signature of Inventor 3
Date	Date	Date

Signature of Inventor 4
Date

SE 3254687 v1


I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the United States Code, Section 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Signature of Inventor 1	Signature of Inventor 2 	Signature of Inventor 3
Date	Date 9/5/01	Date

Signature of Inventor 4
Date

SP 1254687 v1

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the United States Code, Section 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3 
Date	Date	Date 9/6/01

Signature of Inventor 4 
Date 9/7/01

SF-4254687 v1

SEQUENCE LISTING

<110> Dean, Michael
Allikmets, Rando
Bates, Susan E.
Fojo, Antonio T.
The Government of the United States of America
as represented by the Secretary of the
Department of Health and Human Services

<120> A Novel ATP-Binding Cassette Protein Responsible for
Cytotoxin Resistance

<130> 015280-382100PC

<140> US 09/856,927
<141> 2001-05-29

<150> US 60/110,473
<151> 1998-11-30

<150> WO PCT/US99/28107
<151> 1999-11-24

<160> 6

<170> PatentIn Ver. 2.1

<210> 1
<211> 2719
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (205)..(2172)
<223> MXR1

<400> 1
tttaggaacg caccgtgcac atgcttggtg gtcttgtaa gtggaaactg ctgctttaga 60
gtttgttttg aaggtccggg tgactcatcc caacatttac atccttaatt gttaaagcgc 120
tgccctccgag cgcacgcacg ctgagatcct gagcctttgg ttaagaccga gctctattaa 180
gctgaaaaga taaaaactct ccag atg tct tcc agt aat gtc gaa gtt ttt 231
Met Ser Ser Ser Asn Val Glu Val Phe
1 5
atc cca gtg tca caa gga aac acc aat ggc ttc ccc gcg aca gtt tcc 279
Ile Pro Val Ser Gln Gly Asn Thr Asn Gly Phe Pro Ala Thr Val Ser
10 15 20 25
aat gac ctg aag gca ttt act gaa gga gct gtg tta agt ttt cat aac 327
Asn Asp Leu Lys Ala Phe Thr Glu Gly Ala Val Leu Ser Phe His Asn
30 35 40
atc tgc tat cga gta aaa ctg aag agt ggc ttt cta cct tgt cga aaa 375
Ile Cys Tyr Arg Val Lys Leu Lys Ser Gly Phe Leu Pro Cys Arg Lys
45 50 55

09556927.001901

cca gtt gag aaa gaa ata tta tcg aat atc aat ggg atc atg aaa cct	423
Pro Val Glu Lys Glu Ile Leu Ser Asn Ile Asn Gly Ile Met Lys Pro	
60 65 70	
ggc ctc aac gcc atc ctg gga ccc aca ggt gga gcc aaa tct tcg tta	471
Gly Leu Asn Ala Ile Leu Gly Pro Thr Gly Gly Gly Lys Ser Ser Leu	
75 80 85	
tta gat gtc tta gct gca agg aaa gat cca agt gga tta tct gga gat	519
Leu Asp Val Leu Ala Ala Arg Lys Asp Pro Ser Gly Leu Ser Gly Asp	
90 95 100 105	
gtt ctg ata aat gga gca ccg cga cct gcc aat ttc aaa tgt aat tca	567
Val Leu Ile Asn Gly Ala Pro Arg Pro Ala Asn Phe Lys Cys Asn Ser	
110 115 120	
ggc tac gtg gta caa gat gat gtt gtg atg ggc act ctg acg gtg aga	615
Gly Tyr Val Val Gln Asp Asp Val Val Met Gly Thr Leu Thr Val Arg	
125 130 135	
gaa aac tta cag ttc tca gca gct ctt cgg ctt gca aca act atg acg	663
Glu Asn Leu Leu Gln Phe Ser Ala Ala Leu Arg Leu Ala Thr Thr Met Thr	
140 145 150	
aat cat gaa aaa aac gaa cgg att aac agg gtc att gaa gag tta ggt	711
Asn His Glu Lys Asn Glu Arg Ile Asn Arg Val Ile Glu Glu Leu Gly	
155 160 165	
ctg gat aaa gtg gca gac tcc aag gtt gga act cag ttt atc cgt ggt	759
Leu Asp Lys Val Ala Asp Ser Lys Val Gly Thr Gln Phe Ile Arg Gly	
170 175 180 185	
gtg tct gga gga gaa aga aaa agg act agt ata gga atg gag ctt atc	807
Val Ser Gly Gly Glu Arg Lys Arg Thr Ser Ile Gly Met Glu Leu Ile	
190 195 200	
act gat cct tcc atc ttg tcc ttg gat gag cct aca act ggc tta gac	855
Thr Asp Pro Ser Ile Leu Ser Leu Asp Glu Pro Thr Thr Gly Leu Asp	
205 210 215	
tca agc aca gca aat gct gtc ctt ttg ctc ctg aaa agg atg tct aag	903
Ser Ser Thr Ala Asn Ala Val Leu Leu Leu Leu Lys Arg Met Ser Lys	
220 225 230	
cag gga cga aca atc atc ttc tcc att cat cag cct cga tat tcc atc	951
Gln Gly Arg Thr Ile Ile Phe Ser Ile His Gln Pro Arg Tyr Ser Ile	
235 240 245	
ttc aag ttg ttt gat agc ctc acc tta ttg gcc tca gga aga ctt atg	999
Phe Lys Leu Phe Asp Ser Leu Thr Leu Leu Ala Ser Gly Arg Leu Met	
250 255 260 265	
ttc cac ggg cct gct cag gag gcc ttg gga tac ttt gaa tca gct ggt	1047
Phe His Gly Pro Ala Gln Glu Ala Leu Gly Tyr Phe Glu Ser Ala Gly	
270 275 280	
tat cac tgt gag gcc tat aat aac cct gca gac ttc ttc ttg gac atc	1095
Tyr His Cys Glu Ala Tyr Asn Asn Pro Ala Asp Phe Phe Leu Asp Ile	
285 290 295	

09856927.031901

att aat gga gat tcc act gct gtg gca tta aac aga gaa gaa gac ttt Ile Asn Gly Asp Ser Thr Ala Val Ala Leu Asn Arg Glu Glu Asp Phe 300 305 310	1143
aaa gcc aca gag atc ata gag cct tcc aag cag gat aag cca ctc ata Lys Ala Thr Glu Ile Ile Glu Pro Ser Lys Gln Asp Lys Pro Leu Ile 315 320 325	1191
gaa aaa tta gcg gag att tat gtc aac tcc tcc ttc tac aaa gag aca Glu Lys Leu Ala Glu Ile Tyr Val Asn Ser Ser Phe Tyr Lys Glu Thr 330 335 340 345	1239
aaa gct gaa tta cat caa ctt tcc ggg ggt gag aag aag aag aag atc Lys Ala Glu Leu His Gln Leu Ser Gly Gly Glu Lys Lys Lys Lys Ile 350 355 360	1287
aca gtc ttc aag gag atc agc tac acc acc tcc ttc tgt cat caa ctc Thr Val Phe Lys Glu Ile Ser Tyr Thr Thr Ser Phe Cys His Gln Leu 365 370 375	1335
aga tgg gtt tcc aag cgt tca ttc aaa aac ttg ctg ggt aat ccc cag Arg Trp Val Ser Lys Arg Ser Phe Lys Asn Leu Leu Gly Asn Pro Gln 380 385 390	1383
gcc tct ata gct cag atc att gtc aca gtc gta ctg gga ctg gtt ata Ala Ser Ile Ala Gln Ile Ile Val Thr Val Val Leu Gly Leu Val Ile 395 400 405	1431
ggg gcc att tac ttt ggg cta aaa aat gat tct act gga atc cag aac Gly Ala Ile Tyr Phe Gly Leu Lys Asn Asp Ser Thr Thr Gly Ile Gln Asn 410 415 420 425	1479
aga gct ggg gtt ctc ttc ttc ctg acg acc aac cag tgt ttc agc agt Arg Ala Gly Val Leu Phe Phe Leu Thr Thr Asn Gln Cys Phe Ser Ser 430 435 440	1527
gtt tca gcc gtg gaa ctc ttt gtg gta gag aag aag ctc ttc ata cat Val Ser Ala Val Glu Leu Phe Val Val Glu Lys Lys Leu Phe Ile His 445 450 455	1575
gaa tac atc agc gga tac tac aga gtg tca tct tat ttc ctt gga aaa Glu Tyr Ile Ser Gly Tyr Tyr Arg Val Ser Ser Tyr Phe Leu Gly Lys 460 465 470	1623
ctg tta tct gat tta tta ccc atg agg atg tta cca agt att ata ttt Leu Leu Ser Asp Leu Leu Pro Met Arg Met Leu Pro Ser Ile Ile Phe 475 480 485	1671
acc tgt ata gtg tac ttc atg tta gga ttg aag cca aag gca gat gcc Thr Cys Ile Val Tyr Phe Met Leu Gly Leu Lys Pro Lys Ala Asp Ala 490 495 500 505	1719
ttc ttc gtt atg atg ttt acc ctt atg atg gtg gct tat tca gcc agt Phe Phe Val Met Met Phe Thr Leu Met Met Val Ala Tyr Ser Ala Ser 510 515 520	1767
tcc atg gca ctg gcc ata gca gca ggt cag agt gtg gtt tct gta gca Ser Met Ala Leu Ala Ile Ala Ala Gly Gln Ser Val Val Ser Val Ala 525 530 535	1815

aca ctt ctc atg acc atc tgt ttt gtg ttt atg atg att ttt tca ggt 1863
 Thr Leu Leu Met Thr Ile Cys Phe Val Phe Met Met Ile Phe Ser Gly
 540 545 550

ctg ttg gtc aat ctc aca acc att gca tct tgg ctg tca tgg ctt cag 1911
 Leu Leu Val Asn Leu Thr Thr Ile Ala Ser Trp Leu Ser Trp Leu Gln
 555 560 565

tac ttc agc att cca cga tat gga ttt acg gct ttg cag cat aat gaa 1959
 Tyr Phe Ser Ile Pro Arg Tyr Gly Phe Thr Ala Leu Gln His Asn Glu
 570 575 580 585

ttt ttg gga caa aac ttc tgc cca gga ctc aat gca aca gga aac aat 2007
 Phe Leu Gly Gln Asn Phe Cys Pro Gly Leu Asn Ala Thr Gly Asn Asn
 590 595 600

cct tgt aac tat gca aca tgt act ggc gaa gaa tat ttg gta aag cag 2055
 Pro Cys Asn Tyr Ala Thr Cys Thr Gly Glu Glu Tyr Leu Val Lys Gln
 605 610 615

ggc atc gat ctc tca ccc tgg ggc ttg tgg aag aat cac gtg gcc ttg 2103
 Gly Ile Asp Leu Ser Pro Trp Gly Leu Trp Lys Asn His Val Ala Leu
 620 625 630

gct tgt atg att gtt att ttc ctc aca att gcc tac ctg aaa ttg tta 2151
 Ala Cys Met Ile Val Ile Phe Leu Thr Ile Ala Tyr Leu Lys Leu Leu
 635 640 645

ttt ctt aaa aaa tat tct taaatttccc cttaattcag tatgatttat 2199
 Phe Leu Lys Lys Tyr Ser
 650 655

cctcacataa aaaagaagca ctttgattga agtattcaat caagtttttt tgttgttttc 2259

tggtcccttg ccatcacact gttgcacagc agcaattggt ttaaagagat acattttttag 2319

aaatcacaaac aaactgaatt aaacatgaaa gaacccaaga catcatgtat cgcataattag 2379

ttaatctcct cagacagtaa ccatggggaa gaaatctggt ctaattttatt aatctaaaaa 2439

aggagaattg aattctggaa actcctgaca agttattact gtctctggca tttgtttcct 2499

catctttaa atgaatagg aggttagtag cccttcagtc ttaatacttt atgatgctat 2559

ggtttgccat tattttaatat atgacaaatg tattaatgct atactggaaa tgtaaaattg 2619

aaaatatgtt ggaaaaaaga ttctgtctta tagggtaaaa aaagccaccg gtgatagaaa 2679

aaaaatcttt ttgataagca cattaaagtt aatagaactt 2719

<210> 2

<211> 655

<212> PRT

<213> Homo sapiens

<400> 2

Met Ser Ser Ser Asn Val Glu Val Phe Ile Pro Val Ser Gln Gly Asn

1

5

10

15

Thr Asn Gly Phe Pro Ala Thr Val Ser Asn Asp Leu Lys Ala Phe Thr
 20 25 30
 Glu Gly Ala Val Leu Ser Phe His Asn Ile Cys Tyr Arg Val Lys Leu
 35 40
 Lys Ser Gly Phe Leu Pro Cys Arg Lys Pro Val Glu Lys Glu Ile Leu
 50 55 60
 Ser Asn Ile Asn Gly Ile Met Lys Pro Gly Leu Asn Ala Ile Leu Gly
 65 70 75 80
 Pro Thr Gly Gly Gly Lys Ser Ser Leu Leu Asp Val Leu Ala Ala Arg
 85 90 95
 Lys Asp Pro Ser Gly Leu Ser Gly Asp Val Leu Ile Asn Gly Ala Pro
 100 105 110
 Arg Pro Ala Asn Phe Lys Cys Asn Ser Gly Tyr Val Val Gln Asp Asp
 115 120 125
 Val Val Met Gly Thr Leu Thr Val Arg Glu Asn Leu Gln Phe Ser Ala
 130 135 140
 Ala Leu Arg Leu Ala Thr Thr Met Thr Asn His Glu Lys Asn Glu Arg
 145 150 155 160
 Ile Asn Arg Val Ile Glu Glu Leu Gly Leu Asp Lys Val Ala Asp Ser
 165 170 175
 Lys Val Gly Thr Gln Phe Ile Arg Gly Val Ser Gly Gly Glu Arg Lys
 180 185 190
 Arg Thr Ser Ile Gly Met Glu Leu Ile Thr Asp Pro Ser Ile Leu Ser
 195 200 205
 Leu Asp Glu Pro Thr Thr Gly Leu Asp Ser Ser Thr Ala Asn Ala Val
 210 215 220
 Leu Leu Leu Leu Lys Arg Met Ser Lys Gln Gly Arg Thr Ile Ile Phe
 225 230 235 240
 Ser Ile His Gln Pro Arg Tyr Ser Ile Phe Lys Leu Phe Asp Ser Leu
 245 250 255
 Thr Leu Leu Ala Ser Gly Arg Leu Met Phe His Gly Pro Ala Gln Glu
 260 265 270
 Ala Leu Gly Tyr Phe Glu Ser Ala Gly Tyr His Cys Glu Ala Tyr Asn
 275 280 285
 Asn Pro Ala Asp Phe Phe Leu Asp Ile Ile Asn Gly Asp Ser Thr Ala
 290 295 300
 Val Ala Leu Asn Arg Glu Glu Asp Phe Lys Ala Thr Glu Ile Ile Glu
 305 310 315 320
 Pro Ser Lys Gln Asp Lys Pro Leu Ile Glu Lys Leu Ala Glu Ile Tyr
 325 330 335

09856927-091401

Val	Asn	Ser	Ser	Phe	Tyr	Lys	Glu	Thr	Lys	Ala	Glu	Leu	His	Gln	Leu	
			340					345					350			
Ser	Gly	Gly	Glu	Lys	Lys	Lys	Lys	Ile	Thr	Val	Phe	Lys	Glu	Ile	Ser	
		355					360					365				
Tyr	Thr	Thr	Ser	Phe	Cys	His	Gln	Leu	Arg	Trp	Val	Ser	Lys	Arg	Ser	
	370					375					380					
Phe	Lys	Asn	Leu	Leu	Gly	Asn	Pro	Gln	Ala	Ser	Ile	Ala	Gln	Ile	Ile	
	385				390					395					400	
Val	Thr	Val	Val	Leu	Gly	Leu	Val	Ile	Gly	Ala	Ile	Tyr	Phe	Gly	Leu	
				405				410						415		
Lys	Asn	Asp	Ser	Thr	Gly	Ile	Gln	Asn	Arg	Ala	Gly	Val	Leu	Phe	Phe	
		420						425				430				
Leu	Thr	Thr	Asn	Gln	Cys	Phe	Ser	Ser	Val	Ser	Ala	Val	Glu	Leu	Phe	
	435						440					445				
Val	Val	Glu	Lys	Lys	Leu	Phe	Ile	His	Glu	Tyr	Ile	Ser	Gly	Tyr	Tyr	
	450					455					460					
Arg	Val	Ser	Ser	Tyr	Phe	Leu	Gly	Lys	Leu	Leu	Ser	Asp	Leu	Leu	Pro	
	465				470					475					480	
Met	Arg	Met	Leu	Pro	Ser	Ile	Ile	Phe	Thr	Cys	Ile	Val	Tyr	Phe	Met	
			485					490						495		
Leu	Gly	Leu	Lys	Pro	Lys	Ala	Asp	Ala	Phe	Phe	Val	Met	Met	Phe	Thr	
		500						505					510			
Leu	Met	Met	Val	Ala	Tyr	Ser	Ala	Ser	Ser	Met	Ala	Leu	Ala	Ile	Ala	
	515						520				525					
Ala	Gly	Gln	Ser	Val	Val	Ser	Val	Ala	Thr	Leu	Leu	Met	Thr	Ile	Cys	
	530					535					540					
Phe	Val	Phe	Met	Met	Ile	Phe	Ser	Gly	Leu	Leu	Val	Asn	Leu	Thr	Thr	
	545				550					555					560	
Ile	Ala	Ser	Trp	Leu	Ser	Trp	Leu	Gln	Tyr	Phe	Ser	Ile	Pro	Arg	Tyr	
			565					570						575		
Gly	Phe	Thr	Ala	Leu	Gln	His	Asn	Glu	Phe	Leu	Gly	Gln	Asn	Phe	Cys	
			580					585					590			
Pro	Gly	Leu	Asn	Ala	Thr	Gly	Asn	Asn	Pro	Cys	Asn	Tyr	Ala	Thr	Cys	
	595						600					605				
Thr	Gly	Glu	Glu	Tyr	Leu	Val	Lys	Gln	Gly	Ile	Asp	Leu	Ser	Pro	Trp	
	610					615					620					
Gly	Leu	Trp	Lys	Asn	His	Val	Ala	Leu	Ala	Cys	Met	Ile	Val	Ile	Phe	
	625				630					635					640	
Leu	Thr	Ile	Ala	Tyr	Leu	Lys	Leu	Leu	Phe	Leu	Lys	Lys	Tyr	Ser		
			645						650					655		

```
<220>
<221> CDS
<222> (1) .. (444)
<223> MXR1
```

<210> 4
<211> 147
<212> PRT
<213> Mus sp.

<400> 4
Phe Gly Leu Gly Ala Glu Ala Tyr Thr Ala Ser Ser Met Ala Leu Ala
1 5 10 15
Ile Ala Thr Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu Met Thr
20 25 30
Ile Ala Phe Val Phe Met Met Leu Phe Ser Gly Leu Leu Val Asn Leu
35 40 45
Arg Thr Ile Gly Pro Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile Pro
50 55 60
Arg Tyr Gly Phe Thr Ala Leu Gln Tyr Asn Glu Phe Leu Gly Gln Glu
65 70 75 80
Phe Cys Pro Gly Phe Asn Val Thr Asp Asn Ser Thr Cys Val Asn Ser
85 90 95
Tyr Ala Ile Cys Thr Gly Asn Glu Tyr Leu Ile Asn Gln Gly Ile Glu
100 105 110
Leu Ser Pro Trp Gly Leu Trp Lys Asn His Val Ala Leu Ala Cys Met
115 120 125
Ile Ile Ile Phe Leu Thr Ile Ala Tyr Leu Lys Leu Leu Phe Leu Lys
130 135 140
Lys Tyr Ser
145

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer
ABCPR1

<400> 5
acgcaccgtg cacatgcttg 20

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer
ABCPR1

<400> 6
acagtgtgat ggcaaggaa cag 23

0856927.091201